| US5254463A (en)* | 1981-09-18 | 1993-10-19 | Genentech, Inc. | Method for expression of bovine growth hormone |
| GB8308235D0 (en)* | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5639639A (en)* | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
| EP0578328B1 (en)* | 1983-11-02 | 1999-12-29 | Applied Research Systems ARS Holding N.V. | Material and methods for the production of a heterodimeric human LH with a Met42 Val55 alpha subunit |
| US6455282B1 (en) | 1983-11-02 | 2002-09-24 | Genzyme Corporation | Cells, vectors and methods for producing biologically active TSH |
| US4840896A (en)* | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US4923805A (en)* | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| DE3520404C2 (en)* | 1984-06-08 | 1994-06-16 | Genzyme Corp | Pigs ß-FSH |
| US5489529A (en)* | 1984-07-19 | 1996-02-06 | De Boer; Herman A. | DNA for expression of bovine growth hormone |
| US5807715A (en)* | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0173494A3 (en)* | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en)* | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6808901B1 (en)* | 1984-09-03 | 2004-10-26 | Celltech R&D Limited | Production of chimeric antibodies |
| US5498600A (en)* | 1984-10-12 | 1996-03-12 | Zymogenetics, Inc. | Biologically active mosaic proteins |
| EP0487116B1 (en)* | 1984-10-12 | 1999-12-29 | ZymoGenetics, Inc. | Biologically active PDGF analogs in eucaryotic cells |
| US5187263A (en)* | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| DE3439843A1 (en)* | 1984-10-31 | 1986-04-30 | Boehringer Mannheim Gmbh, 6800 Mannheim | PLASMIDE FOR INCREASED PRODUCTION OF PENICILLIN G-AMIDASE |
| US5045633A (en)* | 1985-02-25 | 1991-09-03 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5169939A (en)* | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| US5618920A (en)* | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3689123T2 (en)* | 1985-11-01 | 1994-03-03 | Xoma Corp | MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE. |
| US5576195A (en)* | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| FI98829C (en)* | 1986-01-27 | 1997-08-25 | Chiron Corp | Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity |
| US4946778A (en)* | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en)* | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| ATE87659T1 (en)* | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
| US5869620A (en)* | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL84285A (en)* | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
| IL85035A0 (en)* | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5091513A (en)* | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en)* | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1988009344A1 (en)* | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5258498A (en)* | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US6657050B1 (en) | 1987-05-29 | 2003-12-02 | Tanox, Inc. | Chimeric viral-neutralizing immunoglobulins |
| US5834599A (en)* | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
| US5981278A (en)* | 1987-05-29 | 1999-11-09 | Tanox, Inc. | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS |
| CA1341235C (en)* | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5336603A (en)* | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| DE3744595A1 (en)* | 1987-12-31 | 1989-07-13 | Andreas Dr Plueckthun | METHOD FOR THE GENETIC ENGINEERING OF ANTIBODY |
| EP0327797B1 (en)* | 1988-01-05 | 2003-09-03 | Roche Diagnostics GmbH | Method for the preparation of proteins or protein-containing gene products |
| US5843708A (en)* | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| GB8800077D0 (en)* | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| US5750375A (en)* | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US6004781A (en)* | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
| US5567584A (en)* | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| EP0325224B1 (en)* | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| AU3342689A (en)* | 1988-03-24 | 1989-10-16 | Igen Incorporated | Luminescent chimeric proteins |
| US5582862A (en) | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| US5372812A (en)* | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
| US4975369A (en)* | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US5811265A (en)* | 1988-08-19 | 1998-09-22 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| US5609869A (en)* | 1988-08-19 | 1997-03-11 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| AU623698B2 (en) | 1988-09-02 | 1992-05-21 | Chiron Corporation | Macrophage-derived inflammatory mediator (mip-2) |
| WO1990002569A1 (en) | 1988-09-06 | 1990-03-22 | International Genetic Engineering, Inc. | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| EP0368684B2 (en)* | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US20030229208A1 (en)* | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en)* | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6291160B1 (en)* | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| WO1990014443A1 (en)* | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
| US6969586B1 (en) | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291161B1 (en)* | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US6680192B1 (en) | 1989-05-16 | 2004-01-20 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| CA2034484C (en)* | 1989-06-19 | 2000-08-15 | Maurits W. Geerlings | Radioimmunotherapy using .alpha.-particles emission |
| US7247475B2 (en)* | 1989-07-28 | 2007-07-24 | Wyeth | Method for producing monoclonal antibodies |
| US6475787B1 (en)* | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| US5580774A (en)* | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
| KR927003613A (en)* | 1989-08-23 | 1992-12-18 | 더 제너랄 호스피탈 코오퍼레이숀 | CD4 polypeptides, glycosylated human CD4 molecules, fragments thereof, fusion proteins, gene sequences, and uses thereof of non-human primates |
| ATE236249T1 (en) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | TFN-BINDING PROTEINS |
| US7005560B1 (en) | 1989-10-27 | 2006-02-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7037722B1 (en) | 1989-10-27 | 2006-05-02 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5202422A (en)* | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
| US6995014B1 (en) | 1989-10-27 | 2006-02-07 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5959177A (en)* | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| FR2655660B1 (en)* | 1989-12-11 | 1992-03-20 | Rhone Poulenc Sante | NOVEL POLYPEPTIDES, DNA SEQUENCES FOR THEIR EXPRESSION, PROCESS FOR THEIR PREPARATION AND THEIR USE. |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU7791991A (en)* | 1990-04-24 | 1991-11-11 | Stratagene | Methods for phenotype creation from multiple gene populations |
| GB9206318D0 (en)* | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6916605B1 (en)* | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5595887A (en)* | 1990-07-16 | 1997-01-21 | Bionebraska, Inc. | Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment |
| ATE153536T1 (en)* | 1990-11-27 | 1997-06-15 | Biogen Inc | HIV-INDUCED SYNZYTIA BLOCKING ANTI-CD-4 ANTIBODIES |
| US6403771B1 (en) | 1991-02-19 | 2002-06-11 | Actinium Pharmaceuticals, Limited | Method and means for site directed therapy |
| DE69230142T2 (en) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | METHOD FOR PRODUCING SPECIFIC BINDING PAIRS |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en)* | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en)* | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en)* | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| IE922437A1 (en)* | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5756096A (en)* | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US6136310A (en)* | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| EP0656367A1 (en) | 1991-08-22 | 1995-06-07 | Becton, Dickinson and Company | Method and composition for cancer therapy and for prognosticating responses to cancer theraphy |
| US20070031409A1 (en)* | 1991-09-26 | 2007-02-08 | Stichting Rega Vzw | Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments |
| US6764681B2 (en)* | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US6025165A (en)* | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
| ES2313867T3 (en)* | 1991-12-02 | 2009-03-16 | Medical Research Council | ANTI-AUTO ANTIBODY PRODUCTION OF ANTIBODY SEGMENT REPERTORIES EXPRESSED ON THE PAYMENT SURFACE. |
| AU3326693A (en)* | 1991-12-12 | 1993-07-19 | Scripps Research Institute, The | Bifunctional antithrombotic molecules and antithrombotic polypeptides |
| US5869619A (en)* | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (en)* | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
| US5871734A (en)* | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US5583031A (en)* | 1992-02-06 | 1996-12-10 | President And Fellows Of Harvard College | Empty major histocompatibility class II heterodimers |
| US5932214A (en)* | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| US5733743A (en)* | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9215541D0 (en)* | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| CA2100709C (en)* | 1992-07-27 | 2004-03-16 | Maurits W. Geerlings | Method and means for site directed therapy |
| US5437951A (en)* | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US5639641A (en)* | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| WO1994012520A1 (en)* | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| JPH08507680A (en) | 1993-01-12 | 1996-08-20 | バイオジェン インコーポレイテッド | Recombinant anti-VLA4 antibody molecule |
| ATE249838T1 (en)* | 1993-05-12 | 2003-10-15 | Chiron Corp | PRESERVED MOTIF OF THE HEPATITIS C VIRUS E2/NS1 REGION |
| EP0703925B1 (en) | 1993-06-03 | 1999-08-18 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US5827690A (en)* | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2185116A1 (en)* | 1994-03-08 | 1995-09-14 | Thomas P. Wallace | Recombinant humanized anti-fb5 antibodies |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| USRE39548E1 (en)* | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US6080560A (en)* | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US6140075A (en)* | 1994-07-25 | 2000-10-31 | Monsanto Company | Method for producing antibodies and protein toxins in plant cells |
| ES2251723T3 (en)* | 1994-08-12 | 2006-05-01 | Immunomedics, Inc. | SPECIFIC HUMANIZED ANTIBODIES AND ANTIBODIES FOR B-cell LYMPHOMA AND LEUKEMIA CELLS. |
| US8771694B2 (en)* | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US7597886B2 (en)* | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7820798B2 (en)* | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6017697A (en) | 1994-11-14 | 2000-01-25 | Eli Lilly And Company | Excitatory amino acid receptor protein and related nucleic acid compounds |
| US6258529B1 (en) | 1994-12-01 | 2001-07-10 | Oravax, Inc. | PCR amplification of rearranged genomic variable regions of immunoglobulin genes |
| US20030086922A1 (en)* | 1994-12-02 | 2003-05-08 | David B. Ring | Method of promoting an immune response with a bispecific antibody |
| AU4415796A (en)* | 1994-12-07 | 1996-06-26 | Bionebraska, Inc. | Production of c-terminal amidated peptides from recombinant protein constructs |
| US20030144483A1 (en)* | 1995-05-04 | 2003-07-31 | Medarex, Inc. | Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US7153508B2 (en)* | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| US7175847B1 (en)* | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US7060808B1 (en)* | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7368111B2 (en)* | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| JPH09124509A (en)* | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | Hepatitis treatment |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en)* | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US7964190B2 (en)* | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US5968511A (en)* | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US5961976A (en)* | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| CA2257357C (en)* | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
| GB9712818D0 (en)* | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| CA2266339A1 (en)* | 1996-09-20 | 1998-03-26 | The General Hospital Corporation | Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US5977319A (en)* | 1996-10-21 | 1999-11-02 | Cambridge Antibody Technology Limited | Specific binding members for estradiol; materials and methods |
| US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| JPH10150984A (en)* | 1996-11-19 | 1998-06-09 | Hagiwara Yoshihide | Production of antibody molecule |
| ES2300122T3 (en)* | 1997-03-20 | 2008-06-01 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | RECOMBINANT AND IMMUNOCATED PLAYING ANTIBODIES AGAINST CD-22 CARRIER CELLS AND TUMORS. |
| US5866412A (en)* | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US5955355A (en)* | 1997-03-27 | 1999-09-21 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US5914394A (en)* | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| US5939316A (en)* | 1997-03-27 | 1999-08-17 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US6593132B1 (en) | 1997-04-30 | 2003-07-15 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| US6156546A (en)* | 1997-05-16 | 2000-12-05 | Washington State University Research Foundation | Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni |
| US5891646A (en)* | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
| US6528271B1 (en)* | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| US7147854B2 (en)* | 1997-06-23 | 2006-12-12 | Yes Biotech Laboratories Ltd. | Topical treatment of psoriasis using neutralizing antibodies to interleukin-8 |
| US6103466A (en)* | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
| EP2045322B1 (en)* | 1997-07-14 | 2015-07-01 | Université de Liège | Double-muscling in mammals |
| US20070067859A1 (en)* | 1997-07-14 | 2007-03-22 | Michel Georges | Double-muscling in mammals |
| WO1999009153A1 (en) | 1997-08-21 | 1999-02-25 | Fred Hutchinson Cancer Research Center | ISOLATION AND EXPRESSION OF A DISABLED PROTEIN GENE mDabl AND METHODS |
| US20030027262A1 (en)* | 1997-09-18 | 2003-02-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6756361B1 (en) | 1997-10-14 | 2004-06-29 | Nabi | Enterococcus antigens and vaccines |
| EP1025220B1 (en) | 1997-10-21 | 2007-01-03 | The University Court Of The University Of Glasgow | JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF |
| WO1999027105A2 (en) | 1997-11-21 | 1999-06-03 | Genset | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| CA2309228A1 (en) | 1997-11-28 | 1999-06-10 | Genset S.A. | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| US7790856B2 (en)* | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en)* | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7179892B2 (en)* | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6761888B1 (en)* | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20080050367A1 (en)* | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en)* | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6051228A (en)* | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US20040176572A1 (en)* | 1998-03-16 | 2004-09-09 | Freimer Nelson B. | Methods of compositions for diagnosing and treating chromosome-18p related disorders |
| JP2002506875A (en) | 1998-03-16 | 2002-03-05 | ミレニアム ファーマシューティカルズ インク． | Methods and compositions for diagnosis and treatment of chromosome 18p-related disorders |
| US20030224001A1 (en)* | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| US20050059802A1 (en)* | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ZA200007412B (en)* | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6197947B1 (en) | 1998-06-01 | 2001-03-06 | The Rockefeller University | Translation initiation factor 4AIII and methods of use thereof |
| JP2000000097A (en) | 1998-06-15 | 2000-01-07 | Nippon Zoki Pharmaceut Co Ltd | Nef-binding protein, dna encoding the protein and monoclonal antibody against the same protein |
| US8609614B2 (en)* | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
| US6803448B1 (en)* | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| US6727349B1 (en)* | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| EP1974747B1 (en) | 1998-08-11 | 2012-06-27 | Biogen Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| PL346339A1 (en)* | 1998-08-31 | 2002-02-11 | Biogen | Method of modulating memory effector t-cells and compositions |
| EP1114153A2 (en)* | 1998-09-18 | 2001-07-11 | The Rockefeller University | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| US20010036647A1 (en)* | 1998-10-22 | 2001-11-01 | Prabhakara V. Choudary | Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof |
| DE69941903D1 (en)* | 1998-11-09 | 2010-02-25 | Biogen Idec Inc | TREATMENT OF PATIENTS OBTAINING BONE MARROW TRANSPLANTATION OR TRANSPLANTATION OF PERIPHERAL BLOOD TEMM CELLS WITH ANTI-CD20 ANTIBODIES |
| PT1616572E (en)* | 1998-11-09 | 2010-11-11 | Biogen Idec Inc | Chimeric anti-cd20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia |
| US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| TR200200735T2 (en) | 1998-12-23 | 2002-06-21 | Pfizer Inc. | Human monoclonal antibodies for CTLA-4 |
| EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en)* | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| JP2002540764A (en) | 1999-02-12 | 2002-12-03 | ジェネティックス・インスチチュート・インコーポレーテッド | Humanized immunoglobulin reacting with B7 molecule and therapeutic method using the same |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US6531125B1 (en) | 1999-03-02 | 2003-03-11 | Twinstrand Therapeutics Inc. | Antiviral ricin-like proteins |
| WO2001077137A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en)* | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| KR20140094647A (en) | 1999-03-25 | 2014-07-30 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | Human antibodies that bind human IL-12 and methods for producing |
| DE50013935D1 (en) | 1999-04-13 | 2007-02-15 | Wilex Ag | DIAGNOSTIC AND THERAPEUTIC USE OF ANTIBODIES TO THE UROKINASE RECEPTOR |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2373815A1 (en) | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| CA2305716A1 (en) | 1999-05-28 | 2000-11-28 | University Of Guelph | Method for assay of wbpm |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20040001826A1 (en)* | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| FR2797402B1 (en) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A CONDITION ASSOCIATED WITH A DEGENERATIVE, NEUROLOGICAL OR AUTOIMMUNE DISEASE |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| US7605238B2 (en)* | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ATE354655T1 (en) | 1999-08-24 | 2007-03-15 | Medarex Inc | HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES |
| JP2004504003A (en) | 1999-09-24 | 2004-02-12 | モルフォゲン ファーマスーティカルズ インコーポレイテッド | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| US6342587B1 (en) | 1999-10-22 | 2002-01-29 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products and uses thereof |
| US6346249B1 (en) | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
| CA2389550A1 (en) | 1999-11-05 | 2001-05-17 | The General Hospital Corporation | Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| CA2369050A1 (en) | 2000-02-02 | 2001-08-09 | Vanderbilt University | Methods for preventing or attenuating pathoangiogenic conditions |
| ATE521634T1 (en) | 2000-02-11 | 2011-09-15 | Biogen Idec Inc | HETEROLOGUE POLYPEPTIDE OF THE TNF FAMILY |
| US8623373B2 (en)* | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| JP2003524018A (en) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | Antibodies specific for the ED-B domain of fibronectin, complexes containing said antibodies, and uses thereof for detecting and treating angiogenesis |
| US20030212022A1 (en)* | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| EP1267839B1 (en)* | 2000-03-24 | 2007-10-03 | Biosphere Medical, Inc. | Microspheres for active embolization |
| WO2001088191A1 (en)* | 2000-03-29 | 2001-11-22 | The United States Of America As Represented By The Department Of Veterans Affairs | A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿ |
| US20050043262A1 (en)* | 2000-03-29 | 2005-02-24 | Weiss Robert H. | Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| AU6197800A (en) | 2000-05-10 | 2001-11-20 | Mayo Foundation | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| US20030012781A1 (en)* | 2000-06-06 | 2003-01-16 | Anderson Darrell | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
| EP1176200A3 (en) | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances |
| CN1451043A (en) | 2000-06-29 | 2003-10-22 | 艾博特公司 | Dual specificity antibodies and methods of making and using |
| CA2417357A1 (en) | 2000-08-08 | 2002-02-14 | St. Jude Children's Research Hospital | Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof |
| JP2004527456A (en)* | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Treatment of hyperproliferative diseases with EGF receptor antagonists |
| US6911204B2 (en)* | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
| JP2004506021A (en)* | 2000-08-11 | 2004-02-26 | ファブリル インコーポレイテッド | Methods and compositions for altering T cell mediated pathology |
| KR100886276B1 (en) | 2000-08-11 | 2009-03-04 | 기린 파마 가부시끼가이샤 | Polypeptides Regulating Phosphoric Acid, Calcium Metabolism, Calcification and Vitamin D Metabolism and DNA Encoding It |
| ES2361925T3 (en) | 2000-08-25 | 2011-06-24 | Basf Plant Science Gmbh | POLINUCLEOTIDES OF PLANTS CODING PRENIL PROTEASAS. |
| EP1197550A3 (en)* | 2000-08-25 | 2002-11-20 | Pfizer Products Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| JP2003000268A (en)* | 2000-08-25 | 2003-01-07 | Pfizer Prod Inc | Method and composition for diagnosing and treating disease related to neovascularization |
| AU2001289034A1 (en)* | 2000-09-12 | 2002-03-26 | Joseph A. Beavo | Novel pdes and uses thereof |
| GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
| US6610472B1 (en)* | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
| AU4155602A (en)* | 2000-11-01 | 2002-06-18 | Elusys Therapeutics Inc | Method of producing biospecific molecules by protein trans-splicing |
| US20050136431A1 (en)* | 2000-11-03 | 2005-06-23 | Oakley Robert H. | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| US7018812B2 (en) | 2000-11-03 | 2006-03-28 | Duke University | Modified G-protein coupled receptors |
| US7163800B2 (en)* | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| CA2429544C (en)* | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| US20050196755A1 (en)* | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| EP2412384A1 (en) | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US20040253242A1 (en)* | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US7396917B2 (en)* | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| DK1642910T3 (en) | 2000-12-05 | 2012-05-07 | Alexion Pharma Inc | Rationally designed antibodies |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (en)* | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
| EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
| JP4986370B2 (en) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Uses of RGM and its modulators |
| US7279324B2 (en)* | 2001-01-23 | 2007-10-09 | Duke University | Nucleic acid encoding G-protein coupled receptor with modified DRY motif |
| US20030104402A1 (en)* | 2001-01-23 | 2003-06-05 | University Of Rochester | Methods of producing or identifying intrabodies in eukaryotic cells |
| AU2002255495A1 (en)* | 2001-02-02 | 2002-08-19 | University Of Rochester | Methods of identifying regulator molecules |
| JP2005503116A (en) | 2001-02-09 | 2005-02-03 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Human G protein chemokine receptor (CCR5) HDGNR10 |
| WO2002069904A2 (en)* | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| AU2002254132A1 (en)* | 2001-03-06 | 2002-09-19 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| WO2002072787A2 (en)* | 2001-03-13 | 2002-09-19 | Sierra Sciences, Inc. | Telomerase expression repressor proteins and methods of using the same |
| US20080008704A1 (en)* | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en)* | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US20090081199A1 (en)* | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| WO2002083704A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| CZ20033119A3 (en) | 2001-04-24 | 2005-01-12 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and TNF alpha |
| US7256257B2 (en)* | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| DE10121255A1 (en)* | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | Use of alpha 1-antichymotrypsin polypeptide or nucleic acids encoding the polypeptide, or of a cell expressing the polypeptide, or of antibody against the polypeptide, for diagnosing, treating or preventing poorly-healing wounds |
| US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
| GB0111628D0 (en)* | 2001-05-11 | 2001-07-04 | Scancell Ltd | Binding member |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US6972324B2 (en)* | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| WO2002094376A2 (en)* | 2001-05-22 | 2002-11-28 | Duke University | Compositions and methods for promoting or inhibiting ndpk |
| EP1395274A2 (en)* | 2001-05-22 | 2004-03-10 | Duke University | Compositions and methods for inhibiting metastasis |
| GB0112844D0 (en)* | 2001-05-25 | 2001-07-18 | Psimei Pharmaceuticals Plc | Neutron capture therapy |
| EP1572874B1 (en) | 2001-05-25 | 2013-09-18 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7745398B2 (en)* | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| WO2003000916A2 (en)* | 2001-06-21 | 2003-01-03 | Sierra Sciences, Inc. | Telomerase expression repressor proteins and methods of using the same |
| EP1417342A4 (en) | 2001-07-17 | 2005-07-06 | Gen Hospital Corp | Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| JP2005510249A (en)* | 2001-07-20 | 2005-04-21 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． | Attenuated rabies virus with mutated nuclear protein at the phosphorylation site for vaccination against rabies and gene therapy in the central nervous system |
| CA2454618C (en)* | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| EP1423432A4 (en)* | 2001-07-26 | 2006-01-11 | Lilly Co Eli | Interleukin-1 beta antibodies |
| MXPA04002489A (en) | 2001-09-20 | 2004-11-22 | Immunex Corp | Selection of cells expressing heteromeric polypeptides. |
| WO2003029456A1 (en)* | 2001-10-01 | 2003-04-10 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
| WO2003028537A2 (en) | 2001-10-01 | 2003-04-10 | The General Hospital Corporation | Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| WO2003040341A2 (en) | 2001-11-07 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis a virus antibodies |
| CA2466578A1 (en)* | 2001-11-15 | 2003-05-30 | Becton, Dickinson And Company | Methods and devices for the integrated discovery of cell culture environments |
| EP1542719A4 (en) | 2001-12-05 | 2006-06-21 | Baylor College Medicine | METHODS AND COMPOSITIONS FOR REGULATING OS FORMATION BY MODULATING THE SYMPATHETIC TONUS |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| EP1465634B1 (en) | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| GB0130543D0 (en) | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| ES2545090T3 (en) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Albumin and GCSF fusion proteins |
| JP4527982B2 (en) | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | Antibody to fibroblast growth factor-23 |
| US6578724B1 (en)* | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
| US7135174B2 (en)* | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| US20040009498A1 (en)* | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| AU2003209340A1 (en)* | 2002-01-18 | 2003-09-02 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
| US20080260731A1 (en)* | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US20080254027A1 (en)* | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| US20070148171A1 (en)* | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US8093357B2 (en)* | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en)* | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| JP2005534283A (en) | 2002-03-11 | 2005-11-17 | フィロジェン ソチエタ ペル アツィオニ | Selective targeting of tumor vasculature using antibody molecules |
| MY139983A (en)* | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| AU2003220487A1 (en)* | 2002-03-19 | 2003-10-08 | Cengent Therapeutics, Inc. | Discrete bayesian analysis of data |
| US20030182669A1 (en)* | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
| AU2003218456A1 (en)* | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
| IL164287A0 (en)* | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| EP2270049A3 (en) | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| AU2003221575B2 (en) | 2002-05-02 | 2010-06-10 | Dalia Barsyte | Teneurin C-terminal associated peptides (TCAP) and uses thereof |
| PL210412B1 (en)* | 2002-05-24 | 2012-01-31 | Schering Corp | Neutralizing human anti-igfr antibody |
| US7290215B2 (en)* | 2002-06-03 | 2007-10-30 | Microsoft Corporation | Dynamic wizard interface system and method |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (en) | 2002-07-18 | 2011-11-30 | Merus B V | Recombinant production of mixtures of antibodies |
| WO2004009619A2 (en)* | 2002-07-19 | 2004-01-29 | Cellzome Ag | Protein complexes of the tip60 transcriptional activator protein |
| TWI430810B (en) | 2002-07-19 | 2014-03-21 | Abbott Lab S A | Treatment of tnf-alpha related disorders |
| SI2357006T1 (en) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP1539947A4 (en)* | 2002-08-15 | 2006-09-06 | Epitomics Inc | Humanized rabbit antibodies |
| EP2305836A1 (en) | 2002-08-20 | 2011-04-06 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| AU2003273299B2 (en)* | 2002-09-05 | 2010-04-01 | Medimmune, Llc | Methods of preventing or treating cell malignancies by administering CD2 antagonists |
| US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| JP2005538738A (en)* | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス，インコーポレーテッド | Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment |
| US20040053359A1 (en)* | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
| US20040053363A1 (en)* | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
| EP1545575A4 (en) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE |
| US7514233B2 (en) | 2002-09-26 | 2009-04-07 | K.U. Leuven Research & Development | Integrase cofactor |
| US20060235208A1 (en)* | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US20050262577A1 (en)* | 2002-09-27 | 2005-11-24 | Christian Guelly | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| US7541440B2 (en)* | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| AU2003294232A1 (en) | 2002-10-16 | 2004-05-04 | Euro-Celtique S.A. | Antibodies that bind cell-associated CA 125/O722P and methods of use thereof |
| JP2006516187A (en) | 2002-10-29 | 2006-06-29 | アメリカ合衆国 | Lutzomia longipalpis polypeptide and methods of use |
| EP2351583A1 (en) | 2002-11-26 | 2011-08-03 | Facet Biotech Corporation | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| PT1570267E (en)* | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Assay for identifying antibody producing cells |
| MXPA05005923A (en) | 2002-12-06 | 2005-09-21 | Millennium Pharm Inc | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy. |
| AU2002953431A0 (en)* | 2002-12-19 | 2003-01-09 | Murdoch University | BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof |
| WO2004058171A2 (en) | 2002-12-20 | 2004-07-15 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
| EP2500440B1 (en) | 2002-12-20 | 2015-12-16 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004065551A2 (en)* | 2003-01-21 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| ZA200505782B (en)* | 2003-02-01 | 2006-09-27 | Neuralab Ltd | Active immunization to generate antibodies to soluble A-beta |
| AU2004212953B2 (en) | 2003-02-14 | 2010-03-11 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
| DK1594542T3 (en) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antibody-drug conjugates and their use in the treatment of cancer |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20070275460A1 (en)* | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en)* | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| DE10311248A1 (en)* | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody |
| US8067544B2 (en) | 2003-03-19 | 2011-11-29 | Curagen Corporation | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
| GEP20094629B (en) | 2003-03-19 | 2009-03-10 | Biogen Idec Inc | Nogo receptor binding protein |
| US20080081841A1 (en) | 2003-03-20 | 2008-04-03 | Badache Ali | Materials and Methods for Modulating Cell Motility |
| CA2521826C (en) | 2003-04-11 | 2013-08-06 | Jennifer L. Reed | Recombinant il-9 antibodies and uses thereof |
| SE0301087D0 (en) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
| MXPA05011406A (en) | 2003-04-23 | 2005-12-12 | Medarex Inc | Humanized antibodies to interferon alpha receptor-1 (ifnar-1). |
| EP1635868A1 (en) | 2003-04-30 | 2006-03-22 | Uwe Zangemeister-Wittke | Methods for treating cancer using an immunotoxin |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PL1625166T3 (en) | 2003-05-12 | 2015-08-31 | Helion Biotech Aps | Antibodies to masp-2 |
| ES2451993T3 (en) | 2003-05-16 | 2014-03-28 | Mayo Foundation For Medical Education And Research | Low doses of IgM antibodies to treat demyelinating disorders |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| KR20140033239A (en) | 2003-06-27 | 2014-03-17 | 암젠 프레몬트 인코포레이티드 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| GB0315450D0 (en)* | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en)* | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005010040A1 (en)* | 2003-07-15 | 2005-02-03 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
| US20050058658A1 (en)* | 2003-07-15 | 2005-03-17 | Barros Research Institute | Compositions and methods for immunotherapy of human immunodeficiency virus (HIV) |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| EP1498133A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma Deutschland GmbH | Use of a pak inhibitor for the treatment of a joint disease |
| US7619059B2 (en)* | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| CA2445420A1 (en)* | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
| US7727752B2 (en)* | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
| JP5576010B2 (en) | 2003-08-04 | 2014-08-20 | ザ・ホスピタル・フォー・シック・チルドレン | Lafora disease gene |
| JP2007511738A (en) | 2003-08-08 | 2007-05-10 | ジーンニュース インコーポレーテッド | Biomarkers for osteoarthritis and uses thereof |
| EP1651276A4 (en)* | 2003-08-08 | 2009-05-06 | Barnes Jewish Hospital | EMULSION PARTICLES FOR IMAGING AND THERAPY AND METHODS OF USE THEREOF |
| ES2291917T3 (en)* | 2003-09-05 | 2008-03-01 | Cellzome Ag | TREATMENT OF NEURODEGENERATIVE DISEASES. |
| EP1514561A1 (en) | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| BRPI0414446A (en) | 2003-09-18 | 2006-11-14 | Genmab As | methods for screening for a therapeutic agent, for suppressing the polynucleotide sequence, for treating a non-steroidal cancer, for screening for binding of an agent specifically to a polynucleotide, and for determining whether a patient is at risk for developing or having a non-steroidal cancer, pharmaceutical composition, uses of a therapeutic agent, an antisense molecule or a cell that expresses and / or contains the antisense molecule, at least one of the immunogenic membrane proteins, fragments, derivatives or homologues thereof or from a cell containing and / or expressing at least one of the immunogenic membrane proteins or fragments, derivatives or homologues thereof and an agent or antibody, agent, and kit for identifying a patient at risk of developing or have non-steroidal cancer |
| AU2004275828B2 (en)* | 2003-09-23 | 2010-04-29 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
| US8101720B2 (en)* | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CN102517381A (en) | 2003-10-07 | 2012-06-27 | 千年药品公司 | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| PL1673450T3 (en)* | 2003-10-14 | 2010-10-29 | Baxalta Inc | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| WO2005037313A2 (en) | 2003-10-17 | 2005-04-28 | University Court Of The University Of Edinburgh | Tissue repair by modulation of beta-1 integrin biological function |
| AU2004316290C1 (en) | 2003-11-06 | 2012-02-02 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| AR046833A1 (en) | 2003-11-10 | 2005-12-28 | Schering Corp | ANTI-INTERLEUQUINA ANTIBODIES-10 |
| US20060199194A1 (en)* | 2003-11-10 | 2006-09-07 | Q-Rna, Inc. | Methods of detection using immuno-Q-Amp technology |
| US20050214805A1 (en)* | 2003-11-10 | 2005-09-29 | Q-Rna, Inc. | Methods of detection employing immuno-Q-Amp technology |
| AU2004291107B2 (en) | 2003-11-14 | 2010-09-30 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| US20050272054A1 (en) | 2003-11-26 | 2005-12-08 | Applera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| EP1631311A4 (en) | 2003-12-10 | 2007-04-11 | Millennium Pharm Inc | Humanized anti-ccr2 antibodies and methods of use |
| US7427670B2 (en)* | 2003-12-19 | 2008-09-23 | Cytochroma Inc. | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
| WO2005077981A2 (en)* | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AU2005205533B2 (en) | 2004-01-07 | 2012-03-22 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specific monoclonal antibody and uses thereof |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| AU2004315111B2 (en)* | 2004-01-29 | 2010-03-04 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of GPR49 |
| US20070280927A1 (en)* | 2004-01-29 | 2007-12-06 | Cellzome Ag | Treatment Of Neurodegenerative Diseases By The Use Of Atp7a |
| EP1718329A4 (en)* | 2004-02-06 | 2008-09-10 | Astellas Us Llc | Methods of treating skin disorders |
| CN102816241B (en) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | Albumin fusion proteins |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| EP2275445A3 (en) | 2004-03-12 | 2012-02-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| DK1735348T3 (en)* | 2004-03-19 | 2012-07-16 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
| AU2005227326B2 (en)* | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005092443A1 (en)* | 2004-03-26 | 2005-10-06 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of laptm4b |
| US7973139B2 (en)* | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| BRPI0508761A (en) | 2004-03-31 | 2007-08-14 | Genentech Inc | humanized antibody, composition comprising a humanized antibody, isolated nucleic acid, vector, host cell, humanized antibody production process, tgf-beta dysfunction treatment method, tgf-beta detection method, manufactured article and method of treating cancer |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| TWI556829B (en) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | Multiple-variable dose regimen for treating tnfα-related disorders |
| US20080038265A1 (en)* | 2004-04-09 | 2008-02-14 | Reilly Edward B | Antibodies to Erythropoietin Receptor and Uses Thereof |
| US20060018902A1 (en)* | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| ES2442386T3 (en) | 2004-04-23 | 2014-02-11 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr | Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo. |
| JP4836942B2 (en)* | 2004-04-30 | 2011-12-14 | コーセラ， インコーポレイテッド | Methods and compositions for the control of fetal development by modulation of relaxin |
| US20080020383A1 (en)* | 2004-05-04 | 2008-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment |
| EP1745154B1 (en) | 2004-05-07 | 2012-08-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
| US7662921B2 (en)* | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
| GB0410627D0 (en) | 2004-05-12 | 2004-06-16 | Scancell Ltd | Specific binding members |
| GB0412973D0 (en)* | 2004-06-10 | 2004-07-14 | Celltech R&D Ltd | Identification of antibody producing cells |
| ES2415665T3 (en) | 2004-06-21 | 2013-07-26 | Proteome Sciences Plc | Screening procedures using c-abl, fyn and sky in combination with tau protein |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| RS52593B (en) | 2004-06-24 | 2013-04-30 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| EP2287195B1 (en) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| US7973134B2 (en)* | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
| US6986264B1 (en)* | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
| ME00226B (en) | 2004-07-15 | 2011-02-10 | Medarex Llc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| EP2322217A3 (en) | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| CA2576193A1 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| CA2575300A1 (en)* | 2004-08-09 | 2006-02-16 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of degs inhibitors |
| CA2478458A1 (en)* | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| TWI374935B (en)* | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI364458B (en)* | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (en) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | Production of polypeptides |
| US7432359B2 (en) | 2004-09-06 | 2008-10-07 | Kirin Pharma Kabushiki Kaisha | Anti-A33 antibody |
| EP2145954A1 (en) | 2004-09-06 | 2010-01-20 | Kyowa Hakko Kirin Co., Ltd. | Anti-A33 antibody |
| BRPI0515104A (en)* | 2004-09-09 | 2008-07-08 | Univ Washington | method for producing all-trans- (13,14) dihydroretinol, isolated polypeptide, isolated polynucleotide, expression construct, cultured prokaryotic or eukaryotic cell, vector, isolated host cell, method for producing a retsat polypeptide, antibody, method for identifying agonists or antagonists of a eukaryotic retsat polypeptide, pharmaceutical composition, and, methods for treating a neoplastic disease in a mammalian individual, for treating retinal disease or blindness in a mammalian individual, for treating a retinal disease or blindness in a mammalian individual, for to treat autoimmune disease in a mammalian individual and to treat a skin condition or disorder in a mammalian individual |
| WO2006031994A2 (en)* | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| EP1793850A4 (en) | 2004-09-21 | 2010-06-30 | Medimmune Inc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US7935790B2 (en)* | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
| CA2584211C (en)* | 2004-10-22 | 2014-07-08 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| US20060263792A1 (en)* | 2004-10-29 | 2006-11-23 | Elusys Therapeutics, Inc. | Use of CR1-binding molecules in clearance and induction of immune responses |
| US7709208B2 (en)* | 2004-11-08 | 2010-05-04 | New York University | Methods for diagnosis of major depressive disorder |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| JP2008518609A (en) | 2004-11-09 | 2008-06-05 | フィロゲン エスピーエー | Antibody against tenascin-C |
| US20070135620A1 (en)* | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en)* | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2715776T3 (en) | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatins that have an aminobenzoic acid unit at the N-terminus |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
| CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
| CN101102792A (en)* | 2004-11-19 | 2008-01-09 | 比奥根艾迪克Ma公司 | Treatment for multiple sclerosis |
| WO2006083355A2 (en) | 2004-11-19 | 2006-08-10 | Cornell Research Foundation, Inc. | Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| ES2356830T3 (en) | 2004-12-03 | 2011-04-13 | Schering Corporation | BIOMARCATORS FOR PRESELECTION OF PATIENTS FOR ANTI-IGF-1R THERAPY. |
| CN101072795B (en) | 2004-12-06 | 2014-07-02 | 协和发酵麒麟株式会社 | Human monoclonal antibodies to influenza M2 protein |
| TW200636066A (en)* | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| EP1838348B1 (en)* | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| AR051800A1 (en)* | 2004-12-15 | 2007-02-07 | Wyeth Corp | BETA ANTIBODIES USED TO IMPROVE COGNITION |
| AU2005319404B2 (en) | 2004-12-20 | 2011-10-20 | Amgen Fremont Inc. | Binding proteins specific for human Matriptase |
| US7807789B2 (en)* | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
| EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| CN101103043A (en) | 2005-01-06 | 2008-01-09 | 诺和诺德公司 | KIR binders and methods of using the same |
| AU2006204791A1 (en)* | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
| CN101495498B (en) | 2005-02-07 | 2013-09-18 | 基因信息公司 | Mild osteoarthritis biomarkers and uses thereof |
| US7723486B2 (en) | 2005-02-08 | 2010-05-25 | Optein, Inc. | Antibodies to TGF-β |
| US20090142338A1 (en)* | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| JP2008531730A (en)* | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク． | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| ATE541212T1 (en)* | 2005-03-11 | 2012-01-15 | Sanofi Sa | USING MGC4504 |
| EP1856296A2 (en) | 2005-03-11 | 2007-11-21 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
| AU2005329450A1 (en)* | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
| US8323645B2 (en) | 2005-03-24 | 2012-12-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| US20090099340A1 (en)* | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| ES2707152T3 (en) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| EP2444419A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
| WO2006119968A2 (en)* | 2005-05-09 | 2006-11-16 | Biosphere Medical S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
| EP1882044A1 (en) | 2005-05-11 | 2008-01-30 | sanofi-aventis | Use of a gip promoter polymorphism |
| EP2224008A3 (en) | 2005-05-12 | 2010-12-01 | Murdoch University | Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy |
| CN102961746B (en) | 2005-05-16 | 2016-06-15 | 艾伯维生物技术有限公司 | The purposes of TNF α inhibitor for treatment of erosive polyarthritis |
| CA2726759C (en)* | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
| EP1899376A2 (en) | 2005-06-16 | 2008-03-19 | The Feinstein Institute for Medical Research | Antibodies against hmgb1 and fragments thereof |
| JP5372500B2 (en) | 2005-06-17 | 2013-12-18 | トレラクス リクイデーティング トラスト | ILT3-binding molecules and uses thereof |
| CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| CN103145842A (en)* | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40 binding proteins |
| JP5171621B2 (en) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | Monomethylvaline compound having phenylalanine side chain modification at C-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| CA2902070A1 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2007008604A2 (en)* | 2005-07-08 | 2007-01-18 | Bristol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
| US7868140B2 (en) | 2005-07-18 | 2011-01-11 | Amgen Inc. | Human anti-B7RP1 neutralizing antibodies |
| CA2616005C (en) | 2005-07-18 | 2015-09-22 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
| JP5457671B2 (en) | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | M-CSF specific monoclonal antibody and use thereof |
| WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US20100151495A9 (en)* | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1931710B1 (en) | 2005-08-31 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| WO2007027906A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2007030820A2 (en) | 2005-09-09 | 2007-03-15 | The Johns Hopkins University | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
| US20090162374A1 (en) | 2005-09-14 | 2009-06-25 | Geraghty Daniel E | Specific removal of activated immune cells |
| US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US8906864B2 (en)* | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
| EP1931709B1 (en)* | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| US7973136B2 (en)* | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| DE102005048898A1 (en) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2 variants and their use in the prevention or treatment of thromboembolic disorders and coronary heart disease |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| ES2417147T3 (en)* | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Antibodies with enhanced antibody dependent cell cytotoxicity activity, methods for their production and use |
| EP2319941A3 (en) | 2005-10-21 | 2011-08-17 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
| AR058140A1 (en)* | 2005-10-24 | 2008-01-23 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
| US20090074720A1 (en)* | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| US20080213274A1 (en)* | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| AU2006307018B2 (en) | 2005-10-28 | 2012-10-25 | Meiji Seika Kaisha, Ltd. | Outer coat protein PA5158 of Pseudomonas aeruginosa |
| KR20140012160A (en) | 2005-11-01 | 2014-01-29 | 애브비 바이오테크놀로지 리미티드 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| EP2510934A1 (en) | 2005-11-04 | 2012-10-17 | Biogen Idec MA Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| AU2006311803C1 (en) | 2005-11-04 | 2015-05-14 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| US7939069B2 (en) | 2005-11-09 | 2011-05-10 | Abbott Laboratories | Human BNP immunospecific antibodies |
| EP1957535A1 (en)* | 2005-11-09 | 2008-08-20 | Abbott Laboratories | Human bnp immunospecific antibodies |
| CA2629453C (en) | 2005-11-10 | 2018-03-06 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| JP2009515552A (en)* | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α4β7 integrin-reactive humanized immunoglobulin |
| TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
| RU2442793C2 (en)* | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
| KR101434935B1 (en) | 2005-11-30 | 2014-10-01 | 애브비 인코포레이티드 | Monoclonal Antibodies to Amyloid Beta Proteins and Their Uses |
| WO2007064882A2 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| NZ568016A (en) | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| US20070134249A1 (en)* | 2005-12-08 | 2007-06-14 | Genitope Corporation | Combination therapy and antibody panels |
| CN101326195B9 (en) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | anti-IL-17 antibodies |
| AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
| KR20080089489A (en) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | Specific Therapies for Cancer Treatment Using Integrin Ligands |
| BRPI0707276B1 (en) | 2006-01-27 | 2021-08-31 | Biogen Ma Inc | NOGO RECEPTOR ANTAGONIST FUSION POLYPEPTIDE |
| WO2007090126A2 (en)* | 2006-01-30 | 2007-08-09 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
| US7750116B1 (en)* | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| EP2005184A2 (en) | 2006-03-14 | 2008-12-24 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| KR20080110800A (en) | 2006-03-15 | 2008-12-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | Treatment of patients with paroxysmal nocturnal hematuria with complement inhibitor |
| JP5335662B2 (en) | 2006-03-27 | 2013-11-06 | メドイミューン・リミテッド | Binding structural element for GM-CSF receptor |
| CA2645904A1 (en) | 2006-03-30 | 2007-10-11 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein pa0427 |
| JP2009532358A (en) | 2006-03-31 | 2009-09-10 | マサチューセッツ・インスティテュート・オブ・テクノロジー | Treatment of tumors expressing mutant EGF receptors |
| EP2738179A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| EP2708242A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of ankylosing spondylitis |
| US8784810B2 (en)* | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| EP2420246A1 (en) | 2006-04-20 | 2012-02-22 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 1 protein |
| ES2626527T3 (en) | 2006-04-21 | 2017-07-25 | Intervet International B.V. | Pestivirus species |
| US8022188B2 (en)* | 2006-04-24 | 2011-09-20 | Abbott Laboratories | Immunosuppressant binding antibodies and methods of obtaining and using same |
| US20070254338A1 (en)* | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
| WO2007127335A2 (en)* | 2006-04-27 | 2007-11-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways |
| AU2007244705A1 (en)* | 2006-04-27 | 2007-11-08 | Barnes-Jewish Hospital | Detection and imaging of target tissue |
| AU2007249698A1 (en) | 2006-05-15 | 2007-11-22 | University Of Kentucky | Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration |
| JP2009537123A (en)* | 2006-05-18 | 2009-10-29 | サノフィ−アベンティス | Use of ADAMTS4 gene and protein polymorphisms |
| US7862812B2 (en)* | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| US9217749B2 (en)* | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
| GB0611116D0 (en) | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| AT503690A1 (en) | 2006-06-09 | 2007-12-15 | Biomay Ag | HYPOALLERGENIC MOLECULES |
| JP2009544761A (en) | 2006-06-14 | 2009-12-17 | マクロジェニクス，インコーポレーテッド | Method of treating autoimmune disease using low toxicity immunosuppressive monoclonal antibody |
| JP5597793B2 (en)* | 2006-06-19 | 2014-10-01 | メルク・シャープ・アンド・ドーム・コーポレーション | ILT3-binding molecules and uses thereof |
| PL2029173T3 (en) | 2006-06-26 | 2017-04-28 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
| MX2008016335A (en) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Automatic injection device. |
| ES2427924T3 (en) | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | IGFBP2 biomarker |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| WO2008008360A1 (en) | 2006-07-13 | 2008-01-17 | Wyeth | Production of glycoproteins |
| MY157757A (en) | 2006-07-18 | 2016-07-15 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
| WO2008019326A2 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
| SI2383297T1 (en) | 2006-08-14 | 2013-06-28 | Xencor Inc. | Optimized antibodies that target CD19 |
| KR101368596B1 (en) | 2006-08-18 | 2014-03-17 | 조마 테크놀로지 리미티드 | Prlr-specific antibody and uses thereof |
| AU2007290570C1 (en) | 2006-08-28 | 2013-08-15 | Kyowa Kirin Co., Ltd. | Antagonistic human LIGHT-specific human monoclonal antibodies |
| US20090258442A1 (en)* | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| DK2061810T3 (en) | 2006-09-05 | 2015-02-16 | Alexion Pharma Inc | PRACTICES AND PREPARATIONS FOR THE TREATMENT OF antibody-mediated neuropathies |
| GB0617429D0 (en) | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| US20080064045A1 (en)* | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
| EP3910065A1 (en) | 2006-09-08 | 2021-11-17 | AbbVie Bahamas Ltd. | Interleukin -13 binding proteins |
| NZ597334A (en) | 2006-09-13 | 2014-02-28 | Abbott Lab | Cell culture improvements |
| EP2500416A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| AU2007299843B2 (en)* | 2006-09-18 | 2012-03-08 | Xencor, Inc | Optimized antibodies that target HM1.24 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US7744890B2 (en)* | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
| JP2010506842A (en) | 2006-10-16 | 2010-03-04 | メディミューン，エルエルシー | Molecules with reduced half-life, compositions thereof and uses |
| DK2068921T3 (en) | 2006-10-19 | 2014-09-15 | Csl Ltd | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2666346C (en) | 2006-10-20 | 2016-02-23 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
| WO2008070344A2 (en) | 2006-10-27 | 2008-06-12 | Lpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
| CN101687031B (en) | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
| JP5401319B2 (en)* | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | Glycolytic inhibitors in cell culture |
| ES2397637T3 (en) | 2006-11-10 | 2013-03-08 | Massachusetts Institute Of Technology | PAK inhibitors for use in the treatment of neurodevelopmental disorders |
| CN101641106A (en)* | 2006-11-15 | 2010-02-03 | 功能遗传学股份有限公司 | Anti-TSG101 antibodies and their uses for treatment of viral infections |
| WO2008064306A2 (en)* | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
| JP2010510772A (en) | 2006-11-27 | 2010-04-08 | パトリス リミテッド | Novel glycosylated peptide targets in neoplastic cells |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| CN101678100A (en) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | methods of treating systemic lupus erythematosus |
| KR20140119831A (en) | 2006-12-07 | 2014-10-10 | 노파르티스 아게 | Antagonist antibodies against ephb3 |
| BRPI0720271A2 (en) | 2006-12-14 | 2014-01-28 | Schering Corp | DESIGNED ANTI-TSLP ANTIBODY |
| JP5386364B2 (en) | 2006-12-18 | 2014-01-15 | ジェネンテック， インコーポレイテッド | Anti-Notch3 antagonist antibodies and their use in the prevention and treatment of Notch3-related diseases |
| EA036660B1 (en) | 2007-01-09 | 2020-12-04 | Байоджен Эмэй Инк. | Sp35 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| NZ578065A (en) | 2007-01-16 | 2012-09-28 | Abbott Lab | Methods for treating psoriasis with an antibody which binds to an epitope |
| UA95996C2 (en) | 2007-01-18 | 2011-09-26 | Эли Лилли Энд Компани | Pegylated fab antibody fragment that specifically binds human a-beta peptide |
| BRPI0806596A2 (en) | 2007-01-18 | 2013-07-23 | Merck Patent Ges Mit Berchraenkter Haftung | drug and specific therapy using integrin ligands for cancer treatment |
| JP5361738B2 (en) | 2007-01-22 | 2013-12-04 | ジェネンテック， インコーポレイテッド | Purification of polyelectrolyte precipitates and proteins |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| AR065368A1 (en) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | ANTIBODIES FOR IGE MOLECULES |
| US8685666B2 (en)* | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
| WO2008101184A2 (en)* | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of Southern Illinois University | Arl-1 specific antibodies |
| RS55636B1 (en) | 2007-02-16 | 2017-06-30 | Genzyme Corp | Method of identifying risk for thyroid disorder |
| EP2126105A4 (en) | 2007-02-20 | 2010-11-03 | Anaptysbio Inc | Somatic hypermutation systems |
| SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| PT2426144T (en) | 2007-02-23 | 2019-02-06 | Merck Sharp & Dohme | Engineered anti-il-23p19 antibodies |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| EP2447719B1 (en) | 2007-02-26 | 2016-08-24 | Oxford BioTherapeutics Ltd | Proteins |
| WO2008104386A2 (en)* | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| KR20100014568A (en) | 2007-02-28 | 2010-02-10 | 쉐링 코포레이션 | Engineered anti-il-23r antibodies |
| EP2444410A3 (en) | 2007-02-28 | 2012-08-08 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| CA2679941C (en) | 2007-03-02 | 2016-09-20 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP1972639A3 (en) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| US9023356B2 (en) | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
| GEP20146112B (en) | 2007-03-22 | 2014-06-25 | Ucb Pharma Sa | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof |
| US20090068684A1 (en)* | 2007-03-26 | 2009-03-12 | Cell Signaling Technology, Inc. | Serine and threoninephosphorylation sites |
| WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
| US20080238709A1 (en)* | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
| GB0706070D0 (en)* | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
| RU2476442C2 (en) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Crystalline human il-12 antibodies |
| BRPI0809674A2 (en) | 2007-03-30 | 2014-10-07 | Medimmune Llc | WATER FORMULATION, STERILE, STABLE, PHARMACEUTICAL UNIT FORM, SEALED CONTAINER, KIT, METHOD TO PREVENT, CONTROL, TREAT OR IMPROVE INFLAMMATORY DISORDER, COMPOSITION, PROCESS FOR PREPARATION, PREPARATION FOR PREPARATION, PREPARATION AND PREPARATION |
| JP5221641B2 (en) | 2007-04-02 | 2013-06-26 | フィロゲン エスピーエー | ED-A antigen of fibronectin associated with neovascularization of tumor metastasis |
| EP1985295A1 (en) | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders |
| US7807168B2 (en)* | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
| CN101970000A (en)* | 2007-04-18 | 2011-02-09 | 杨森阿尔茨海默氏症免疫治疗公司 | Prevention and treatment of cerebral amyloid angiopathy |
| US8003097B2 (en)* | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| TW200902708A (en)* | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| US20100143336A1 (en) | 2007-04-26 | 2010-06-10 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
| US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| SG194368A1 (en) | 2007-05-04 | 2013-11-29 | Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa | Engineered rabbit antibody variable domains and uses thereof |
| WO2008143797A1 (en) | 2007-05-11 | 2008-11-27 | Genzyme Corporation | Methods of producing a secreted protein |
| SI2068927T1 (en) | 2007-05-14 | 2016-05-31 | Medimmune, Llc | Methods of reducing eosinophil levels |
| US20090232801A1 (en)* | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US20110064744A1 (en)* | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| PE20090329A1 (en)* | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
| US9163091B2 (en)* | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| AU2008260135A1 (en) | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8604172B2 (en) | 2009-04-17 | 2013-12-10 | Lpath, Inc. | Humanized antibody compositions and methods for binding lysophosphatidic acid |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| US7580304B2 (en)* | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
| NO2631248T3 (en) | 2007-06-15 | 2018-04-14 | | |
| CN101821288A (en) | 2007-06-21 | 2010-09-01 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
| US20080317768A1 (en)* | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
| WO2009005040A1 (en)* | 2007-06-29 | 2009-01-08 | Meiji Seika Kaisha Ltd. | Pseudomonas aeruginosa outer membrane protein pa4710 |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| EA017995B1 (en) | 2007-07-25 | 2013-04-30 | Филоджен С.П.А. | An antigen associated with lung cancers and lymphomas |
| SI2182983T1 (en) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
| CA2694034A1 (en)* | 2007-07-27 | 2009-02-05 | Pfizer Limited | Antibody purification process by precipitation |
| EP2023144A1 (en) | 2007-08-01 | 2009-02-11 | Sanofi-Aventis | Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics |
| CN101835490A (en) | 2007-08-02 | 2010-09-15 | 阿雷斯托生物科学股份有限公司 | Lox and l0xl2 inhibitors and uses thereof |
| JP5576275B2 (en) | 2007-08-03 | 2014-08-20 | オプソナ セラピューティクス リミテッド | Use of TLR-2 antagonists to treat reperfusion injury and tissue damage |
| MX2010001381A (en) | 2007-08-03 | 2010-09-14 | Spirogene Pty Ltd | Genes and proteins of brachyspira hyodysenteriae and uses thereof. |
| AU2008287427B2 (en) | 2007-08-13 | 2014-10-09 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to EphB4 |
| JP5532486B2 (en) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Monoclonal antibody 175 targeting EGF receptor and derivatives and uses thereof |
| MX338395B (en) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses. |
| NZ599756A (en)* | 2007-08-30 | 2013-09-27 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
| GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
| EP2033971A1 (en)* | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application |
| EP3418299B1 (en) | 2007-09-14 | 2024-11-13 | Amgen Inc. | Homogeneous antibody populations |
| ES2395548T3 (en) | 2007-09-24 | 2013-02-13 | Cornell University | Immunogenic proteins of the outer membrane derived from the genome of leptospira and compositions and methods based on them |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
| WO2009046388A1 (en) | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
| CA2701189C (en)* | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JO3076B1 (en)* | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| GB0720250D0 (en) | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| MX2010004514A (en) | 2007-10-23 | 2010-07-28 | Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides. |
| US8361465B2 (en) | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| CN101918443B (en) | 2007-10-30 | 2013-07-17 | 菲洛根股份公司 | Antigen associated with rheumatoid arthritis |
| PT2219452E (en) | 2007-11-05 | 2016-01-26 | Medimmune Llc | Methods of treating scleroderma |
| US8039212B2 (en) | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| EP2217697B1 (en)* | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| WO2009067546A2 (en) | 2007-11-19 | 2009-05-28 | Celera Corpration | Lung cancer markers and uses thereof |
| EP2062920A3 (en) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
| WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
| WO2009079242A2 (en) | 2007-12-05 | 2009-06-25 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
| CA2982321C (en) | 2007-12-14 | 2021-01-05 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| BRPI0822099A2 (en) | 2007-12-21 | 2017-05-23 | Medimmune Ltd | isolated binding member, use of an isolated binding member, method for treating a disorder, isolated nucleic acid molecule, host cell, and method for producing a binding member |
| AU2008342152B2 (en) | 2007-12-25 | 2013-06-27 | Meiji Seika Pharma Co., Ltd. | Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa |
| EP2235059B1 (en) | 2007-12-26 | 2015-02-18 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| US20090203038A1 (en)* | 2007-12-27 | 2009-08-13 | Abbott Laboratories | Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays |
| WO2009083246A1 (en) | 2007-12-31 | 2009-07-09 | Bayer Schering Pharma Aktiengesellschaft | Antibodies to tnf alpha |
| AU2009203350B2 (en) | 2008-01-11 | 2014-03-13 | Gene Techno Science Co., Ltd. | Humanized anti-alpha9 integrin antibodies and the uses thereof |
| EP3181588A1 (en) | 2008-01-11 | 2017-06-21 | Adheron Therapeutics, Inc. | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| CA3108119C (en) | 2008-01-15 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CA2711736A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| DK2245052T3 (en) | 2008-01-25 | 2017-09-11 | Univ Aarhus | SELECTIVE EXOSITE INHIBITATION OF PAPP-A ACTIVITY AGAINST IGFBP-4 |
| WO2009100309A2 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| US20090221620A1 (en) | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| EP2363407A1 (en) | 2008-02-28 | 2011-09-07 | Murdoch University | Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof |
| US8962803B2 (en)* | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| US20090220991A1 (en)* | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| NZ587765A (en) | 2008-03-18 | 2013-02-22 | Abbott Lab | Methods for treating psoriasis |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| US20110020368A1 (en) | 2008-03-25 | 2011-01-27 | Nancy Hynes | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| EP2105742A1 (en)* | 2008-03-26 | 2009-09-30 | Sanofi-Aventis | Use of cathepsin C |
| WO2009117773A1 (en) | 2008-03-27 | 2009-10-01 | Murdoch University | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof |
| EP2604280A3 (en) | 2008-03-27 | 2013-10-16 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| JP2011516078A (en) | 2008-04-10 | 2011-05-26 | セル・シグナリング・テクノロジー・インコーポレイテツド | Compositions and methods for detecting EGFR mutations in cancer |
| AU2008201871A1 (en)* | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| CN104530233B (en) | 2008-04-24 | 2018-01-30 | 株式会社遗传科技 | The amino acid sequence RGD of extracellular matrix protein Humanized antibody specific and its application |
| US20090269786A1 (en)* | 2008-04-25 | 2009-10-29 | The Board Of Trustees Of The University Of Illinois | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies |
| EP2279003A4 (en)* | 2008-05-01 | 2013-04-03 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODIES AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| MY159667A (en) | 2008-05-09 | 2017-01-13 | Abbvie Inc | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
| EP2297186B1 (en) | 2008-05-29 | 2018-08-29 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Expression and assembly of human group c rotavirus-like particles and uses thereof |
| EP2304439A4 (en) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt antibodies |
| CA2728347A1 (en) | 2008-06-16 | 2010-01-14 | Patrys Limited | Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| JP5866601B2 (en) | 2008-06-18 | 2016-02-17 | ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ | Method for producing pharmaceutical composition |
| EP2732823B1 (en) | 2008-06-25 | 2019-08-07 | H. Lundbeck A/S | Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain |
| FR2933702A1 (en)* | 2008-07-08 | 2010-01-15 | Sanofi Aventis | SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR |
| RU2559525C2 (en) | 2008-07-08 | 2015-08-10 | Эббви Инк | Proteins binding prostaglandin e2 and using them |
| EP2982695B1 (en)* | 2008-07-09 | 2019-04-03 | Biogen MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| US8067339B2 (en)* | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
| EP3093351B1 (en) | 2008-07-09 | 2018-04-18 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
| US8148088B2 (en)* | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
| WO2010010469A2 (en)* | 2008-07-25 | 2010-01-28 | Abbott Gmbh & Co. Kg | Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof |
| CN102282172B (en) | 2008-09-07 | 2014-02-19 | 台湾醣联生技医药股份有限公司 | Anti-stretched type I glycosphingolipid antibody, derivatives and uses thereof |
| US20110236376A1 (en)* | 2008-09-08 | 2011-09-29 | Smiley Stephen T | Non-neutralizing immunity to influenza to prevent secondary bacterial pneumonia |
| US20100061995A1 (en)* | 2008-09-08 | 2010-03-11 | Damian Michael Carragher | Immunotherapy To Treat Or Prevent Viral Infection |
| KR20110057244A (en) | 2008-09-19 | 2011-05-31 | 메디뮨 엘엘씨 | Antibodies to DL4 and Uses thereof |
| CN102187224A (en) | 2008-09-22 | 2011-09-14 | 俄勒冈健康科学大学 | Methods for detecting a mycobacterium tuberculosis infection |
| EP2344180A2 (en) | 2008-09-23 | 2011-07-20 | Wyeth LLC | Methods for predicting production of activating signals by cross-linked binding proteins |
| EP2334300B1 (en)* | 2008-09-24 | 2016-02-17 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Composition and method for treatment of preterm labor |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| JP2012504650A (en) | 2008-10-02 | 2012-02-23 | セルタクシス，インコーポレイテッド | Methods for regulating negative chemotaxis of immune cells |
| KR20110091678A (en) | 2008-10-20 | 2011-08-12 | 아보트 러보러터리즈 | Isolation and Purification of Antibodies by Protein A Affinity Chromatography |
| US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| EP2350270B1 (en) | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
| JP5823867B2 (en) | 2008-10-29 | 2015-11-25 | アブリンクス エン．ヴェー． | Formulation of single domain antigen binding molecule |
| EP3199553B1 (en) | 2008-10-29 | 2019-04-24 | Circular Commitment Company | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2009314311B2 (en) | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2010052288A1 (en) | 2008-11-07 | 2010-05-14 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
| PA8849001A1 (en) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | C-MET ANTIBODIES |
| US20100172862A1 (en)* | 2008-11-28 | 2010-07-08 | Abbott Laboratories | Stable antibody compositions and methods of stabilizing same |
| US8401799B2 (en)* | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| JP2012511026A (en)* | 2008-12-05 | 2012-05-17 | エルパス・インコーポレイテッド | Antibody design using anti-antibody crystal structure |
| WO2010078916A1 (en) | 2008-12-19 | 2010-07-15 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| WO2010069331A2 (en) | 2008-12-19 | 2010-06-24 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| BRPI0918122A8 (en) | 2008-12-19 | 2017-01-24 | Macrogenics Inc | diabody, diabody, and dart molecule |
| US20100159485A1 (en)* | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
| GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| CA2748757A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
| US20110275791A1 (en) | 2009-01-06 | 2011-11-10 | Ziad Mallat | A B Cell Depleting Agent for the Treatment of Atherosclerosis |
| EP2379116B1 (en) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| AU2009336800A1 (en) | 2009-01-07 | 2011-07-21 | Philogen S.P.A. | Cancer treatment |
| US20130122052A1 (en) | 2009-01-20 | 2013-05-16 | Homayoun H. Zadeh | Antibody mediated osseous regeneration |
| US20120058131A1 (en) | 2009-01-21 | 2012-03-08 | Oxford Biotherapeutics Ltd | Pta089 protein |
| US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
| CA2750076A1 (en) | 2009-01-26 | 2010-07-29 | Electrophoretics Limited | Methods |
| WO2010087972A2 (en)* | 2009-01-29 | 2010-08-05 | Abbott Laboratories | Il-1 binding proteins |
| US20110165063A1 (en)* | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
| EP2219029A1 (en) | 2009-01-30 | 2010-08-18 | Sanofi-Aventis | Test systems, methods and uses involving AS160 protein |
| WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| CA2983133A1 (en)* | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
| US9079942B2 (en)* | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
| US20120165340A1 (en) | 2009-02-11 | 2012-06-28 | Ludwing Institute For Cancer Research Ltd. | Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis |
| WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| PT2396017E (en) | 2009-02-16 | 2015-10-22 | Cerenis Therapeutics Holding Sa | Apolipoprotein a-i mimics |
| US20110306069A1 (en) | 2009-02-19 | 2011-12-15 | Qingyu Wu | Corin As A Marker For Heart Failure |
| US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
| WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
| US8648176B2 (en) | 2009-02-27 | 2014-02-11 | Massachusetts Institute Of Technology | Engineered proteins with high affinity for DOTA chelates |
| US8835610B2 (en) | 2009-03-05 | 2014-09-16 | Abbvie Inc. | IL-17 binding proteins |
| WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
| WO2010104208A1 (en) | 2009-03-10 | 2010-09-16 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
| EP2408468B1 (en) | 2009-03-19 | 2014-04-30 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | USE OF NKp46 FOR PREVENTING TYPE 1 DIABETES |
| US8748493B2 (en) | 2009-03-20 | 2014-06-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders |
| WO2010111180A1 (en) | 2009-03-24 | 2010-09-30 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against light and uses thereof |
| WO2010112033A2 (en) | 2009-03-31 | 2010-10-07 | Østjysk Innovation A/S | Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x |
| WO2010112034A2 (en) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
| GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| AR075989A1 (en) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | ANTIBODY DKK -1 (DICKKOPF-1) HUMAN DESIGNED BY ENGINEERING |
| AU2010233089B2 (en) | 2009-04-10 | 2016-05-26 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (MMP-1) |
| EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
| TWI559930B (en) | 2009-04-16 | 2016-12-01 | Abbvie Biotherapeutics Inc | Anti-tnf-α antibodies and their uses |
| AU2010236257A1 (en)* | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
| US8362218B2 (en) | 2009-04-17 | 2013-01-29 | New York University School Of Medicine | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof |
| WO2010125566A2 (en) | 2009-04-27 | 2010-11-04 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
| EP2949673A1 (en) | 2009-04-27 | 2015-12-02 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| KR101721906B1 (en)* | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | Automatic injection device |
| CA2757638C (en) | 2009-04-29 | 2017-06-27 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Erg monoclonal antibodies |
| US9125861B2 (en) | 2009-05-04 | 2015-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections |
| KR20160103160A (en) | 2009-05-13 | 2016-08-31 | 젠자임 코포레이션 | Anti-human cd52 immunoglobulins |
| GB0908425D0 (en) | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
| CA2682429A1 (en)* | 2009-05-20 | 2010-11-20 | Gary Levy | An assay for measuring plasma fgl-2 and methods and uses thereof |
| ES2432618T3 (en) | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of a pathology of the inner ear with vestibular deficit |
| LT2432467T (en) | 2009-05-20 | 2018-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders |
| KR20120104491A (en) | 2009-05-25 | 2012-09-21 | 메르크 파텐트 게엠베하 | Continuous administration of cilengitide in cancer treatments |
| US20100317539A1 (en)* | 2009-06-12 | 2010-12-16 | Guo-Liang Yu | Library of Engineered-Antibody Producing Cells |
| JP5785941B2 (en) | 2009-06-17 | 2015-09-30 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Anti-VEGF antibodies and uses thereof |
| US20120156221A1 (en) | 2009-06-19 | 2012-06-21 | Ludivine Perrocheau | Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders |
| JP5918129B2 (en) | 2009-06-22 | 2016-05-18 | メディミューン，エルエルシー | Engineered Fc region for site-specific conjugation |
| JP2012531423A (en)* | 2009-06-24 | 2012-12-10 | エルパス， インコーポレーテッド | Method for increasing neuronal differentiation using antibodies against lysophosphatidic acid |
| US8435961B2 (en)* | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| US8268550B2 (en)* | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
| US20110097329A1 (en) | 2009-06-26 | 2011-04-28 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| US20120107270A1 (en) | 2009-06-30 | 2012-05-03 | Manuela Kaspar | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer |
| SG176947A1 (en) | 2009-07-03 | 2012-01-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| CN102481380A (en) | 2009-07-09 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | In vivo tumor vasculature imaging |
| WO2011008959A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Enhancement of cellular production through mechanotransduction |
| CN104710504B (en) | 2009-07-22 | 2019-09-13 | 锕医药股份有限公司 | The method for being used to prepare radioimmunoassay conjugate |
| WO2011009883A1 (en) | 2009-07-23 | 2011-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease |
| EP2461832B1 (en) | 2009-08-05 | 2017-06-28 | Philogen S.p.A. | Targeting of bone marrow neovasculature |
| EP2464661B1 (en) | 2009-08-13 | 2018-01-17 | The Johns Hopkins University | Methods of modulating immune function with anti-b7-h7cr antibodies |
| DK2464664T3 (en) | 2009-08-13 | 2016-01-18 | Crucell Holland Bv | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT |
| GB0914446D0 (en) | 2009-08-18 | 2009-09-30 | King S College London | Bioconjugates and their uses in imaging |
| US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
| CN102002104A (en) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | Anti-VEGF monoclonal antibody and medicinal composition containing same |
| CN105131112A (en) | 2009-08-29 | 2015-12-09 | Abbvie公司 | Therapeutic dll4 binding proteins |
| WO2011023824A2 (en) | 2009-08-31 | 2011-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells |
| EP2293072A1 (en) | 2009-08-31 | 2011-03-09 | Sanofi-Aventis | Use of cathepsin H |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| LT3023438T (en) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
| KR20140048229A (en)* | 2009-09-14 | 2014-04-23 | 애브비 인코포레이티드 | Methods for treating psoriasis |
| US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
| EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| WO2011040973A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| US8999342B2 (en) | 2009-10-02 | 2015-04-07 | Ludwig Institute For Cancer Research, Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| US8435516B2 (en) | 2009-10-12 | 2013-05-07 | Pfizer Inc. | Cancer treatment |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| US9181306B2 (en) | 2009-10-16 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
| CN104628857A (en) | 2009-10-16 | 2015-05-20 | 法国施维雅药厂 | Monoclonal antibodies to progastrin and their uses |
| CA2775595A1 (en) | 2009-10-20 | 2011-04-28 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
| EP2490696A1 (en) | 2009-10-20 | 2012-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis |
| CN104447996A (en) | 2009-10-23 | 2015-03-25 | 米伦纽姆医药公司 | Anti-GCC antibody molecules and related compositions and methods |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
| GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
| CA2778673A1 (en) | 2009-10-27 | 2011-05-05 | Karen Margrete Miller | Function modifying nav 1.7 antibodies |
| CN102753580A (en) | 2009-10-28 | 2012-10-24 | 亚培生物医疗股份有限公司 | Anti-egfr antibodies and their uses |
| US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
| TW201121568A (en)* | 2009-10-31 | 2011-07-01 | Abbott Lab | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| AU2010315304B2 (en) | 2009-11-04 | 2014-03-27 | Merck Sharp & Dohme Llc | Engineered anti-TSLP antibody |
| WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
| EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| WO2011060206A2 (en)* | 2009-11-13 | 2011-05-19 | U3 Pharma Gmbh | Material and methods for treating or preventing her-3 associated diseases |
| EP2502076B1 (en) | 2009-11-20 | 2018-04-18 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| US20120251562A1 (en) | 2009-11-23 | 2012-10-04 | Philippe Pierre | Inhibitors of the PP1/GADD34 Complex for the Treatment of a Condition Requiring an Immunosuppressive Activity |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| WO2011064395A2 (en) | 2009-11-30 | 2011-06-03 | Inserm | Inhibitors and antagonists of calcium channels in the treatment of asthma |
| US9872905B2 (en) | 2009-12-01 | 2018-01-23 | President And Fellows Of Harvard College | Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186) |
| BR112012013734A2 (en)* | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration. |
| WO2011070049A1 (en) | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| SI2510012T1 (en) | 2009-12-09 | 2017-08-31 | Bayer Pharma Aktiengesellschaft | Anti-c4.4a antibodies and uses thereof |
| WO2011075524A1 (en)* | 2009-12-15 | 2011-06-23 | Abbott Biotechnology Ltd | Improved firing button for automatic injection device |
| ES2594893T3 (en) | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anti HER2 antibodies and their uses |
| WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
| KR101961495B1 (en) | 2009-12-23 | 2019-03-22 | 아비펩 피티와이 리미티트 | Immuno-conjugates and methods for producing them 2 |
| US9005579B2 (en) | 2010-01-05 | 2015-04-14 | Contrafect Corporation | Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria |
| HUE045270T2 (en) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| US20110177614A1 (en)* | 2010-01-15 | 2011-07-21 | The Regents Of The University Of California | Compositions and methods for detecting cancer |
| LT2523661T (en) | 2010-01-15 | 2017-08-10 | INSERM (Institut National de la SantƩ et de la Recherche MƩdicale) | Nkcc inhibitors for the treatment of autism |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| US8846397B2 (en) | 2010-01-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments |
| MX2012008985A (en) | 2010-02-02 | 2012-09-07 | Abbott Biotech Ltd | Methods and compositions for predicting responsiveness to treatment with tnf-î± inhibitor. |
| EP2536432B1 (en) | 2010-02-19 | 2018-08-08 | Cornell University | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| US9624491B2 (en) | 2010-02-26 | 2017-04-18 | Memorial Sloan Kettering Cancer Center | Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets |
| US20110212088A1 (en)* | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| RU2605928C2 (en) | 2010-03-02 | 2016-12-27 | Эббви Инк. | Therapeutic dll4-binding proteins |
| CA2791538C (en) | 2010-03-03 | 2019-04-16 | Neil R. Cashman | Oligomer-specific amyloid beta epitope and antibodies |
| US20130004519A1 (en) | 2010-03-05 | 2013-01-03 | Ruth Chiquet-Ehrismann | Smoci, tenascin-c and brain cancers |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| WO2011113118A1 (en) | 2010-03-19 | 2011-09-22 | Katholieke Universiteit Leuven | Drug tolerance/persistence of fungal biofilms |
| TR201903279T4 (en) | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disulfide stabilized DVD-IG molecules. |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| PT2552959T (en) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | MUC16 ANTIBODIES AND METHODS OF USE |
| WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
| EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| WO2011127412A2 (en) | 2010-04-09 | 2011-10-13 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| MX360403B (en) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Amyloid-beta binding proteins. |
| ES2633105T3 (en) | 2010-04-16 | 2017-09-19 | Biogen Ma Inc. | Antibodies against VLA-4 |
| US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| EP2561076A1 (en) | 2010-04-19 | 2013-02-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
| GB201006768D0 (en) | 2010-04-22 | 2010-06-09 | Cancer Rec Tech Ltd | Method for obtaining dendritic cells |
| CN103038256A (en) | 2010-04-29 | 2013-04-10 | 纳斯瓦克斯有限公司 | Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy |
| US20130266584A1 (en) | 2010-04-30 | 2013-10-10 | Detlef Schuppan | Methods and compositions for treating celiac disease |
| JP6148175B2 (en) | 2010-05-10 | 2017-06-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and compositions for the treatment of fluid retention in and / or under the retina |
| AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
| WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
| GB201008541D0 (en) | 2010-05-21 | 2010-07-07 | Univ Geneve | Diagnostic methods |
| WO2011147889A1 (en) | 2010-05-25 | 2011-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| JP2013534515A (en) | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | Antibody to unprocessed receptor tyrosine kinase c-MET |
| WO2011151395A2 (en) | 2010-06-02 | 2011-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| CN103079594B (en) | 2010-06-03 | 2016-04-13 | 艾伯维生物技术有限公司 | Be used for the treatment of purposes and the compositions of hidradenitis suppurativa (HS) |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| US9127051B2 (en) | 2010-06-09 | 2015-09-08 | Queen Mary & Westfield College, University Of London | Annexin 1 antibody |
| AR081434A1 (en) | 2010-06-10 | 2012-08-29 | Lilly Co Eli | ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT |
| WO2011154485A1 (en) | 2010-06-10 | 2011-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| RU2013101779A (en) | 2010-06-16 | 2014-07-27 | Эббви Инк. | COMPARISON OF PROTEIN SAMPLES |
| WO2011157798A1 (en) | 2010-06-16 | 2011-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for stimulating reepithelialisation during wound healing |
| CN103037887B (en) | 2010-06-25 | 2017-11-10 | 国家医疗保健研究所 | For treating the method and pharmaceutical composition of respiratory tract infection |
| WO2011161427A2 (en) | 2010-06-25 | 2011-12-29 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| WO2012000904A1 (en) | 2010-06-28 | 2012-01-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of glaucoma |
| WO2012004565A1 (en) | 2010-07-06 | 2012-01-12 | Robert White | Cancer biomarker brf1 |
| US9485812B2 (en) | 2010-07-08 | 2016-11-01 | Honda Motor Co., Ltd. | High frequency heating coil |
| KR20140002601A (en) | 2010-07-09 | 2014-01-08 | 바이오겐 이데크 헤모필리아 인코포레이티드 | Chimeric clotting factors |
| NZ718973A (en) | 2010-07-09 | 2019-01-25 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| AU2011279044B2 (en) | 2010-07-15 | 2013-12-19 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods |
| CN103153328A (en) | 2010-07-16 | 2013-06-12 | 默克专利股份有限公司 | Peptide for use in the treatment of breast cancer and/or bone metastases |
| WO2012007880A2 (en) | 2010-07-16 | 2012-01-19 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
| CN103108886B (en) | 2010-07-20 | 2016-08-24 | 赛法隆澳大利亚控股有限公司 | Anti-il-23 heterodimer specific antibody |
| EP2596025B1 (en) | 2010-07-23 | 2018-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
| ES2667100T3 (en) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Covalent Diabodies and Their Uses |
| US20120156130A1 (en) | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
| JP5903718B2 (en) | 2010-08-09 | 2016-04-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for the treatment of HIV-1 infection |
| EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
| ES2564252T3 (en) | 2010-08-12 | 2016-03-21 | Eli Lilly And Company | Anti-beta-amyloid N3pGlu peptide antibodies and uses thereof |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| US20130150554A1 (en) | 2010-08-20 | 2013-06-13 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| KR101719118B1 (en) | 2010-08-23 | 2017-03-22 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Anti-ox40 antibodies and methods of using the same |
| RU2637088C2 (en) | 2010-09-01 | 2017-11-29 | Джензим Корпорейшн | Myocardial infarction treatment using tgf-beta antagonists |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9945842B2 (en) | 2010-09-03 | 2018-04-17 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
| KR20130114143A (en) | 2010-09-20 | 2013-10-16 | 애브비 인코포레이티드 | Purification of antibodies using simulated moving bed chromatography |
| EP2621511A1 (en) | 2010-09-28 | 2013-08-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of bone density related diseases |
| EP2623119B1 (en) | 2010-09-30 | 2017-06-14 | Riken | Drug used in glioma treatment method, glioma examination method, method of delivering a desired material to a glioma |
| EP2622095B1 (en) | 2010-10-01 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
| NZ624752A (en) | 2010-10-19 | 2015-11-27 | Mayo Foundation | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| EP2629801B3 (en) | 2010-10-22 | 2019-11-27 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| AU2011319777B2 (en) | 2010-10-27 | 2016-12-08 | The Research Foundation For The State University Of New York | Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy |
| US20120108651A1 (en) | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
| JP6296536B2 (en) | 2010-11-05 | 2018-03-20 | メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ | Endothelial progenitor cell markers and uses thereof |
| GB201019118D0 (en) | 2010-11-11 | 2010-12-29 | King S College | Conjugates and their uses in molecular imaging |
| WO2012064286A1 (en) | 2010-11-11 | 2012-05-18 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
| EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR THERAPY AGAINST HIV |
| US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
| US9072766B2 (en) | 2010-11-18 | 2015-07-07 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT) |
| TWI589587B (en) | 2010-11-19 | 2017-07-01 | 衛材Ｒ＆Ｄ企管股份有限公司 | Neutralizing anti-ccl20 antibodies |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| CN107459577A (en) | 2010-12-01 | 2017-12-12 | 默沙东公司 | The FC bait antibody display systems of surface anchoring |
| EP2646572B1 (en) | 2010-12-01 | 2017-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of chronic heart failure |
| WO2012072820A1 (en) | 2010-12-03 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of heart failure |
| TW201238973A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| TW201239097A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| TW201241179A (en) | 2010-12-17 | 2012-10-16 | Sanofi Sa | MiRNAs in joint disease |
| TW201238974A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| MX2013007067A (en) | 2010-12-20 | 2013-11-01 | Medimmune Ltd | Anti-il-18 antibodies and their uses. |
| TW201307388A (en) | 2010-12-21 | 2013-02-16 | Abbott Lab | IL-1 binding proteins |
| EP2655607A4 (en) | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K |
| AU2011349049B2 (en) | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| WO2012090939A1 (en) | 2010-12-27 | 2012-07-05 | 国立大学法人名古屋大学 | Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells |
| US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
| JP2014506448A (en) | 2011-01-19 | 2014-03-17 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Binding proteins for inhibitors of clotting factors |
| ES2662004T3 (en) | 2011-01-24 | 2018-04-05 | Abbvie Biotechnology Ltd | Automatic injection devices with overmolded grip surfaces |
| US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| WO2012161755A2 (en) | 2011-02-02 | 2012-11-29 | Emory University | Antagonism of the vip signaling pathway |
| WO2012106669A2 (en) | 2011-02-04 | 2012-08-09 | John Wayne Cancer Institute | Foxc1 antibodies and methods of their use |
| WO2012110824A1 (en) | 2011-02-18 | 2012-08-23 | Astrazeneca Ab | Binding agents with specificity for a nucleic acid modification |
| KR102071081B1 (en) | 2011-03-02 | 2020-01-29 | 버그 엘엘씨 | Interrogatory cell-based assays and uses thereof |
| KR20190006083A (en) | 2011-03-09 | 2019-01-16 | 셀 시그널링 테크놀러지, 인크. | Methods and reagents for creating monoclonal antibodies |
| WO2012125735A1 (en) | 2011-03-15 | 2012-09-20 | Abott Laboratories | An integrated approach to the isolation and purification of antibodies |
| WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| WO2012128810A1 (en) | 2011-03-23 | 2012-09-27 | Abbott Laboratories | Methods and systems for the analysis of protein samples |
| MX361242B (en) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha. |
| EP3536708A1 (en) | 2011-04-19 | 2019-09-11 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
| DK2699253T3 (en) | 2011-04-21 | 2018-07-16 | Univ Rockefeller | STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES |
| US20140127240A1 (en) | 2011-04-21 | 2014-05-08 | Bayer Pharma Aktiengesellschaft | Novel Binder-Drug Conjugates (ADCs) and Use of Same |
| WO2012142662A1 (en) | 2011-04-21 | 2012-10-26 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using them b |
| EP2518157A1 (en) | 2011-04-26 | 2012-10-31 | Sanofi | Test Systems and methods for identifying a compound altering cellular DDR activity |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| WO2012151247A2 (en) | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
| UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | COMPOSITION OF ANTI-α4β7 ANTIBODY |
| GB201107467D0 (en) | 2011-05-05 | 2011-06-15 | Univ Leuven Kath | Novel treatment of pain |
| US9598496B2 (en) | 2011-05-09 | 2017-03-21 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| EP2707711A1 (en) | 2011-05-09 | 2014-03-19 | The Cleveland Clinic Foundation | Serum s100b and uses thereof |
| EP2524699A1 (en) | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| ES2703780T3 (en) | 2011-05-17 | 2019-03-12 | Trion Res Gmbh | Preparation of a vaccine containing trifunctional antibodies with potentiating properties of antigen immunogenicity |
| SG195073A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Deimmunized serum-binding domains and their use for extending serum half-life |
| AR086543A1 (en) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION |
| WO2012164035A1 (en) | 2011-06-01 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| EP2717911A1 (en) | 2011-06-06 | 2014-04-16 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| CN103687621A (en) | 2011-06-08 | 2014-03-26 | 印第安纳大学研究与技术公司 | Monoclonal Antibodies and Antigens for Diagnosis and Treatment of Lung Diseases and Injuries |
| GB201109966D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating pten mutated or deficient cancer |
| LT2717898T (en) | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
| DK2718320T3 (en) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF |
| GB201109965D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating estrogen receptor alpher(ER) positive cancer |
| CA2838973A1 (en) | 2011-06-17 | 2012-12-20 | Adrian L. Harris | Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
| EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| WO2012175711A1 (en) | 2011-06-24 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy |
| RS55716B1 (en) | 2011-06-28 | 2017-07-31 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| BR112013033661A2 (en) | 2011-06-30 | 2017-01-24 | Genzyme Corp | t cell activation inhibitors |
| EP2726502A1 (en) | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| BR112014000474A2 (en) | 2011-07-08 | 2017-02-21 | Bayer Ip Gmbh | relaxin-releasing fusion proteins and their uses |
| AU2012283039A1 (en) | 2011-07-13 | 2014-01-30 | Abbvie Inc. | Methods and compositions for treating asthma using anti-IL-13 antibodies |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| EP2548891A1 (en) | 2011-07-18 | 2013-01-23 | Universiteit Maastricht | Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma. |
| US20150125533A1 (en) | 2011-07-25 | 2015-05-07 | American University In Cairo | Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same |
| CA2842053C (en) | 2011-07-27 | 2018-01-16 | Philogen S.P.A. | Il-12 immunoconjugate |
| US10168329B2 (en) | 2011-08-03 | 2019-01-01 | Quidel Corporation | N-acetyl-D-glucosamine for enhanced specificity of Strep A immunoassay |
| EP2743699A4 (en) | 2011-08-12 | 2015-04-08 | Nat Inst Infectious Diseases | METHOD FOR THE TEST, PREVENTION AND TREATMENT OF ASPERGILLUS FUMIGATUS INFECTIOUS DISEASE, AND COMPOSITION |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| US9599608B2 (en) | 2011-09-21 | 2017-03-21 | Fujirebio Inc. | Antibody against affinity complex |
| MX2014003313A (en) | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Bispecific binding molecules for 5t4 and cd3. |
| JP2014530001A (en) | 2011-09-23 | 2014-11-17 | テクノファージ， インベスティガサン エデセンボルビメント エム ビオテクノロジア，エスエー | Anti-tumor necrosis factor-α agent and use thereof |
| RU2628089C2 (en) | 2011-09-26 | 2017-08-14 | Филоген С.П.А. | Immunocytocins combined therapy |
| EP2748198A2 (en) | 2011-09-27 | 2014-07-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| EP2760889A4 (en) | 2011-09-30 | 2015-04-15 | Teva Pharmaceuticals Australia Pty Ltd | Antibodies against tl1a and uses thereof |
| ES2683035T3 (en) | 2011-10-05 | 2018-09-24 | The Rockefeller University | Dimeric bacteriophage lysines |
| US20140335081A1 (en) | 2011-10-10 | 2014-11-13 | Medlmmune Limited | Treatment For Rheumatoid Arthritis |
| EP2766041B1 (en) | 2011-10-12 | 2018-12-05 | Children's Medical Center Corporation | Combinatorial compositions and methods of treating hemoglobinopathies |
| US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
| CN103890166A (en) | 2011-10-21 | 2014-06-25 | 辉瑞公司 | Addition of iron to improve cell culture |
| EP2768861A1 (en) | 2011-10-21 | 2014-08-27 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
| WO2013063095A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against sclerostin |
| CA2852709A1 (en) | 2011-10-28 | 2013-05-02 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
| US10202643B2 (en) | 2011-10-31 | 2019-02-12 | University Of Utah Research Foundation | Genetic alterations in glioma |
| AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
| EP2773373B1 (en) | 2011-11-01 | 2018-08-22 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| US9221907B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Anti-GPR49 monoclonal antibodies |
| CN104053671A (en) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | Antibodies and methods for treating cancer |
| PL2776065T3 (en) | 2011-11-07 | 2020-12-14 | Medimmune Limited | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| EP2776130A1 (en) | 2011-11-07 | 2014-09-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
| EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
| DK2776466T3 (en) | 2011-11-11 | 2017-11-20 | Ucb Biopharma Sprl | Albumin-binding antibodies and binding fragments thereof |
| TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
| EA201490974A1 (en) | 2011-11-16 | 2014-09-30 | Эмджен Инк. | METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH DELIVERY MUTANT VIII EPIDERMAL GROWTH FACTOR |
| SI2780039T1 (en) | 2011-11-17 | 2018-06-29 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
| AR088941A1 (en) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | ANTI-FGFR2 ANTIBODIES AND THEIR USES |
| EP2599496A1 (en) | 2011-11-30 | 2013-06-05 | Kenta Biotech AG | Novel targets of Acinetobacter baumannii |
| WO2013080050A2 (en) | 2011-11-30 | 2013-06-06 | Universitaetsklinikum Erlangen | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
| ES2784131T3 (en) | 2011-12-05 | 2020-09-22 | X Body Inc | PDGF receptor beta-binding polypeptides |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| WO2013088136A1 (en) | 2011-12-12 | 2013-06-20 | Ahrens Susan | Ligand for dngr-1 receptor |
| RU2014128467A (en) | 2011-12-14 | 2016-02-10 | Сиэтл Дженетикс, Инк. | NEW CONJUGATES BINDING JOINT-ACTIVE JOINT (ADC) AND THEIR APPLICATION |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013102825A1 (en) | 2012-01-02 | 2013-07-11 | Novartis Ag | Cdcp1 and breast cancer |
| EA201491346A1 (en) | 2012-01-10 | 2014-11-28 | Байоджен Айдек Ма Инк. | STRENGTHENING TRANSPORT OF THE THERAPEUTIC MOLECULES THROUGH THE HEMATOENCEPHALIC BARRIER |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
| CN107880124B (en) | 2012-01-27 | 2021-08-13 | 艾伯维德国有限责任两合公司 | Compositions and methods for diagnosing and treating diseases associated with neural mutations |
| CN108324943B (en) | 2012-02-10 | 2024-03-08 | 思进股份有限公司 | Detection and treatment of CD30+ cancers |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP2814842B1 (en) | 2012-02-15 | 2018-08-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
| NO2814844T3 (en) | 2012-02-15 | 2017-12-30 | | |
| GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| CA2864177C (en) | 2012-03-01 | 2019-11-26 | Amgen Research (Munich) Gmbh | Prolonged half-life albumin-binding protein fused bispecific antibodies |
| EP3211002B1 (en) | 2012-03-21 | 2020-05-13 | Ben-Gurion University of The Negev | Peptides derived from the ectodomain of nkp46 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| CA2866753C (en) | 2012-03-27 | 2020-09-22 | Genentech, Inc. | Improved harvest operations for recombinant proteins |
| LT2831113T (en) | 2012-03-28 | 2018-06-25 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
| US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
| SG10201608234UA (en) | 2012-04-02 | 2016-11-29 | Berg Llc | Interrogatory cell-based assays and uses thereof |
| WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
| WO2013152352A1 (en) | 2012-04-06 | 2013-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Live, attenuated rubella vector to express vaccine antigens |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| WO2013155447A1 (en) | 2012-04-13 | 2013-10-17 | Children's Medical Center Corporation | Tiki inhibitors |
| ES2870717T3 (en) | 2012-04-17 | 2021-10-27 | Mayo Found Medical Education & Res | Human antibodies and specific binding sequences thereof for use in stroke and ischemia and ischemic conditions |
| WO2013156867A2 (en) | 2012-04-19 | 2013-10-24 | Inserm | Methods and pharmaceutical compositions for the treatment of hypertension |
| SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| US20150125471A1 (en) | 2012-05-03 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
| US9273140B2 (en) | 2012-05-10 | 2016-03-01 | Fujita Health University | Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D |
| US9890378B2 (en) | 2012-05-11 | 2018-02-13 | Merck Sharp & Dohme Corp. | Surface anchored light chain bait antibody display system |
| US9416189B2 (en) | 2012-05-11 | 2016-08-16 | Microbial Chemistry Research Foundation | Anti-CXADR antibody |
| CA2873623C (en) | 2012-05-14 | 2021-11-09 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| EA037203B1 (en) | 2012-05-15 | 2021-02-18 | Сиэтл Джинетикс, Инк. | Antibody-drug conjugates with self-stabilizing linkers |
| JP6122948B2 (en) | 2012-05-15 | 2017-04-26 | モルフォテック， インコーポレイテッド | Methods for the treatment of gastric cancer |
| WO2013171296A1 (en) | 2012-05-16 | 2013-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of sarcoidosis |
| WO2013177115A2 (en) | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| KR101937733B1 (en) | 2012-05-24 | 2019-01-11 | 마운트게이트 그룹 리미티드 | Compositions and methods related to prevention and treatment of rabies infection |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US10287564B2 (en) | 2012-06-08 | 2019-05-14 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| CN104427995A (en) | 2012-06-08 | 2015-03-18 | 比奥根艾迪克Ma公司 | Chimeric clotting factors |
| CN104582703A (en) | 2012-06-08 | 2015-04-29 | 森索睿翁公司 | H4 receptor inhibitors for treating tinnitus |
| EP2866831A1 (en) | 2012-06-29 | 2015-05-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| WO2014011908A1 (en) | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
| AR091755A1 (en) | 2012-07-12 | 2015-02-25 | Abbvie Inc | PROTEINS OF UNION TO IL-1 |
| EP2881467B1 (en) | 2012-07-30 | 2018-10-31 | National University Corporation Nagoya University | Monoclonal antibody against human midkine |
| WO2014020293A1 (en) | 2012-07-31 | 2014-02-06 | Imperial Innovations Limited | Assay |
| GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2692357A1 (en) | 2012-08-03 | 2014-02-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel anti-plasmodium parasite antibodies |
| ES2775192T3 (en) | 2012-08-16 | 2020-07-24 | Ipierian Inc | Tauopathy treatment procedures |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| KR20150043523A (en) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | Methods to control protein heterogeneity |
| EP2896291B1 (en) | 2012-09-13 | 2019-03-20 | Chugai Seiyaku Kabushiki Kaisha | Gene knock-in non-human animal |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| DK2897978T3 (en) | 2012-09-19 | 2017-05-15 | Abbvie Biotherapeutics Inc | PROCEDURES FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| AU2013318618B2 (en) | 2012-09-24 | 2017-04-06 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| US9594083B2 (en) | 2012-09-28 | 2017-03-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for the treatment of cardiovascular fibrosis |
| NO2760138T3 (en) | 2012-10-01 | 2018-08-04 | | |
| DK2903629T3 (en) | 2012-10-03 | 2019-08-05 | Philogen Spa | Antibody conjugate for use in the treatment of inflammatory bowel disease |
| ES2776029T3 (en) | 2012-10-08 | 2020-07-28 | St Jude Childrens Res Hospital | Therapies based on the control of the stability and function of regulatory T cells by means of a neuropilin-1 axis: semaphorin |
| JP6343615B2 (en) | 2012-10-15 | 2018-06-20 | メディミューン リミテッド | Antibodies against amyloid β |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | Anti-complement c1s antibodies and uses thereof |
| WO2014064192A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction |
| JP6543572B2 (en) | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | Anti-complement C1s antibodies and their uses |
| EP2917195B9 (en) | 2012-11-05 | 2018-05-30 | Pfizer Inc | Spliceostatin analogs |
| TW201431880A (en) | 2012-11-07 | 2014-08-16 | Pfizer | Anti-Notch3 antibodies and antibody-drug conjugates |
| SI2918603T1 (en) | 2012-11-08 | 2018-12-31 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
| GB201220924D0 (en) | 2012-11-21 | 2013-01-02 | Cancer Res Inst Royal | Materials and methods for determining susceptibility or predisposition to cancer |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6408487B2 (en) | 2012-12-18 | 2018-10-24 | ザ ロックフェラー ユニバーシティ | Glycan modified anti-CD4 antibodies for prevention and therapy of HIV |
| JP2016505843A (en) | 2012-12-19 | 2016-02-25 | アンプリミューン， インコーポレイテッド | B7-H4 specific antibodies, and compositions and methods of use thereof |
| WO2014100602A1 (en) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Treatment of egf-receptor dependent pathologies |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| EP2935332B1 (en) | 2012-12-21 | 2021-11-10 | MedImmune, LLC | Anti-h7cr antibodies |
| JP6405319B2 (en) | 2012-12-28 | 2018-10-17 | ザ ユニバーシティー オブ メルボルン | Image analysis for breast cancer prediction |
| US9840559B2 (en) | 2013-02-01 | 2017-12-12 | The Regents Of The University Of California | Anti-CD83 antibodies and use thereof |
| AU2014214530B2 (en) | 2013-02-07 | 2014-10-16 | Csl Limited | IL-11R binding proteins and uses thereof |
| WO2014123227A1 (en) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | Antibodies to human nrg1 protein |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| CN105308068A (en) | 2013-02-13 | 2016-02-03 | 法国化学与生物科技实验室 | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| BR112015019348A2 (en) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | METHODS FOR PRODUCING GLYCOSYLATION MODIFIED AND SIALYLATION ENHANCED PROTEIN, TO ENHANCE SIALYL TRANSFERASE ACTIVITY IN THE MAMMARY GLAND AND TO PRODUCE SIALYL TRANSFERASE, GLYCOSYLATION MODIFIED PROTEIN OR SIALYLATION ENHANCED PROTEIN, COMPOSITION, SIALYL TRANSFERASE, MAMMALIAN, AND TRANSGENE MAMMARY EPITHELIAL |
| EP3339327A3 (en) | 2013-02-28 | 2018-09-19 | National Cancer Center | Antibody against insoluble fibrin |
| WO2014164472A1 (en) | 2013-03-10 | 2014-10-09 | The Board Of Regents Of The University Of Texas System | Biomarkers for chagas disease related cardiomyopathy |
| AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| IL292978A (en) | 2013-03-13 | 2022-07-01 | Univ California | Preparations containing antibodies against cd-38 carfilzomib |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| EP2968526A4 (en) | 2013-03-14 | 2016-11-09 | Abbott Lab | Hcv antigen-antibody combination assay and methods and compositions for use therein |
| EP2971046A4 (en) | 2013-03-14 | 2016-11-02 | Abbott Lab | Hcv core lipid binding domain monoclonal antibodies |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| WO2014151917A1 (en) | 2013-03-14 | 2014-09-25 | Ffe Therapeutics Llc | Compositions and methods for treating angiogenesis-related disorders |
| CA2899449A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| WO2014142882A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
| BR112015023355A8 (en) | 2013-03-14 | 2018-01-30 | Abbott Lab | hcv ns3 recombinant antigens and mutants thereof for enhanced antibody detection. |
| CA2899308C (en) | 2013-03-14 | 2017-04-18 | Abbvie Inc. | Low acidic species adalimumab compositions and uses thereof |
| EP2971077B1 (en) | 2013-03-15 | 2019-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction |
| CA2904532A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
| AU2014233528B2 (en) | 2013-03-15 | 2019-02-28 | Abbvie Biotherapeutics Inc. | Fc variants |
| CN110143999B (en) | 2013-03-15 | 2023-12-05 | 酵活英属哥伦比亚省公司 | Cytotoxic and antimitotic compounds and methods of use thereof |
| AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
| AU2014233503A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| WO2014146575A1 (en) | 2013-03-19 | 2014-09-25 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2014167083A1 (en) | 2013-04-12 | 2014-10-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| WO2014174596A1 (en) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| GB201308259D0 (en) | 2013-05-08 | 2013-06-12 | Iles Raymond K | Cancer diagnosis and monitoring |
| CN105392800B (en) | 2013-05-17 | 2020-07-31 | 国家科学研究中心 | anti-CXC L1, CXC L7 and CXC L8 antibodies and uses thereof |
| MX376808B (en) | 2013-05-24 | 2025-03-07 | Medimmune Llc | ANTI-B7-H5 ANTIBODIES AND THEIR USES. |
| WO2014197849A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| ES2800827T3 (en) | 2013-06-10 | 2021-01-04 | Ipierian Inc | Treatment procedures for a tauopathy |
| JP2016521715A (en) | 2013-06-14 | 2016-07-25 | バイエル ファーマ アクチエンゲゼルシャフト | Anti-TWEAKR antibody and use thereof |
| EP3011334A1 (en) | 2013-06-20 | 2016-04-27 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
| EP3013857B1 (en) | 2013-06-28 | 2021-06-23 | Singapore Health Services Pte Ltd | Trpm4 channel inhibitors for stroke treatment |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| US9919029B2 (en) | 2013-07-26 | 2018-03-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
| EP3030902B1 (en) | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
| TWI592426B (en) | 2013-08-13 | 2017-07-21 | 賽諾菲公司 | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| UA118267C2 (en) | 2013-08-13 | 2018-12-26 | Санофі | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
| EP3046564B1 (en) | 2013-09-16 | 2024-05-22 | INSERM - Institut National de la Santé et de la Recherche Médicale | Inhibitor of the gluk2/gluk5 receptor expression for use in the treatment of epilepsy |
| CA2925087C (en) | 2013-09-24 | 2024-02-13 | The Feinstein Institute For Medical Research | Peptides inhibiting cold-inducible rna binding protein activity |
| EP3049085B9 (en) | 2013-09-26 | 2021-08-18 | Beth Israel Deaconess Medical Center, Inc. | Sgk1 inhibitors in the treatment of long qt syndrome |
| GB201317207D0 (en) | 2013-09-27 | 2013-11-13 | Univ Glasgow | Materials and methods for modulating disc1 turnover |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| PE20160561A1 (en) | 2013-10-11 | 2016-06-03 | Oxford Biotherapeutics Ltd | CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER |
| CN105764503A (en) | 2013-10-15 | 2016-07-13 | 西雅图基因公司 | PEGylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US10344319B2 (en) | 2013-10-28 | 2019-07-09 | Dots Technology Corp. | Allergen detection |
| GB201319374D0 (en) | 2013-11-01 | 2013-12-18 | Univ Nottingham | Glycans as functional cancer targets abd antibodies thereto |
| JPWO2015068781A1 (en) | 2013-11-06 | 2017-03-09 | 国立大学法人大阪大学 | Antibodies with broad neutralizing activity against group 1 of influenza virus type A |
| EP2871189A1 (en) | 2013-11-07 | 2015-05-13 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
| WO2015070069A1 (en) | 2013-11-07 | 2015-05-14 | Abbvie Inc. | Isolation and purification of dvd-igs |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| GB201320061D0 (en) | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EA038994B1 (en) | 2013-11-27 | 2021-11-18 | Айпириэн, Инк. | METHODS FOR TAUPATIA TREATMENT |
| RU2718054C2 (en) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Method of treating nephropathy |
| JP2017502002A (en) | 2013-12-09 | 2017-01-19 | ニューヨーク・ユニバーシティ | Composition and method for phagocytic cell delivery of anti-staphylococcal agents |
| WO2015086727A2 (en) | 2013-12-11 | 2015-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method for patients suffering of a cancer |
| EP3080611B1 (en) | 2013-12-13 | 2018-11-14 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
| EP3080160B1 (en) | 2013-12-13 | 2022-07-06 | Rijksuniversiteit Groningen | Antibodies against staphylococcus aureus and uses thereof |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| CA2932465C (en) | 2013-12-18 | 2023-08-22 | Csl Limited | Methods of treating wounds in a diabetic subject |
| EP3082878B1 (en) | 2013-12-19 | 2022-10-05 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| TW201609805A (en) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | Multifunctional antibodies binding to EGFR and MET |
| BR112016014830A2 (en) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | ANTIBODY DRUG CONJUGATES (ADCS) WITH KSP INHIBITORS |
| CA2935077C (en) | 2013-12-27 | 2022-03-15 | Geoffrey C. Winters | Sulfonamide-containing linkage systems for drug conjugates |
| JP6236540B2 (en) | 2014-01-27 | 2017-11-22 | ファイザー・インク | Bifunctional cytotoxic agent |
| EP3102598A2 (en) | 2014-02-04 | 2016-12-14 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| JP6713931B2 (en) | 2014-02-11 | 2020-06-24 | シアトル ジェネティクス，インコーポレイティド | Selective reduction of proteins |
| IL290116B2 (en) | 2014-02-17 | 2024-06-01 | Seagen Inc | Hydrophilic antibody-drug conjugates |
| US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| MX383829B (en) | 2014-02-28 | 2025-03-14 | Merus Nv | Antibody that binds ERBB-2 and ERBB-3. |
| GB201403815D0 (en) | 2014-03-04 | 2014-04-16 | Mologic Ltd | Assay |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
| WO2015140708A1 (en) | 2014-03-19 | 2015-09-24 | Pfizer Inc. | Method of cell culture |
| RU2723940C2 (en) | 2014-03-21 | 2020-06-18 | Экс-Боди, Инк. | Bispecific antigen-binding polypeptides |
| US9546214B2 (en) | 2014-04-04 | 2017-01-17 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
| KR102239413B1 (en) | 2014-04-10 | 2021-04-12 | 다이이찌 산쿄 가부시키가이샤 | Anti-her3 antibody-drug conjugate |
| EP3131569B1 (en) | 2014-04-16 | 2020-05-27 | Philippe Rouet | Apoo for use in a method for treating cancer and various pathophysiological situations |
| GB201407132D0 (en) | 2014-04-23 | 2014-06-04 | Velgene Biotechnology | Marker for neurodegenerative disorders |
| AU2015249374A1 (en) | 2014-04-24 | 2016-12-01 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| AU2015249946A1 (en) | 2014-04-25 | 2016-11-17 | The Brigham And Women's Hospital Inc. | Methods to manipulate alpha-fetoprotein (AFP) |
| EP3888690A3 (en) | 2014-05-16 | 2021-10-20 | MedImmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| EP3154579A1 (en) | 2014-06-13 | 2017-04-19 | Friedrich Miescher Institute for Biomedical Research | New treatment against influenza virus |
| EP3157535A1 (en) | 2014-06-23 | 2017-04-26 | Friedrich Miescher Institute for Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
| EP3145951A1 (en) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| WO2015199976A1 (en) | 2014-06-24 | 2015-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Target activated microdissection |
| TW201628647A (en) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | anti-IL4-IL13 bispecific antibody |
| AU2015283805B2 (en) | 2014-06-30 | 2021-02-25 | Murdoch Childrens Research Institute | Helicobacter therapeutic |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| WO2016001830A1 (en) | 2014-07-01 | 2016-01-07 | Friedrich Miescher Institute For Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| TN2017000008A1 (en) | 2014-07-17 | 2018-07-04 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
| EP3998273A1 (en) | 2014-07-17 | 2022-05-18 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
| TW201609812A (en) | 2014-07-31 | 2016-03-16 | 安美基研究（慕尼黑）公司 | Optimized cross-species specific bispecific single chain antibody construct |
| TW201609811A (en) | 2014-07-31 | 2016-03-16 | 安美基研究（慕尼黑）公司 | Bispecific single chain antibody construct with enhanced tissue distribution |
| UY36245A (en) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
| ES2726645T3 (en) | 2014-08-01 | 2019-10-08 | Inst Nat Sante Rech Med | An anti-CD45RC antibody to use as a medicine |
| AU2015300915B2 (en) | 2014-08-08 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photo-controlled removal of targets in vitro and in vivo |
| JP6858559B2 (en)* | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | Method for measuring viscosity of protein solution |
| BR112017004270B1 (en) | 2014-09-04 | 2023-03-07 | Stemcell Technologies Inc | METHOD OF ACTIVATION OF T CELLS OR NK CELLS |
| HRP20220123T1 (en) | 2014-09-17 | 2022-04-15 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| US10080790B2 (en) | 2014-09-19 | 2018-09-25 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
| EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
| CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP6941561B2 (en) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Multiple variable IL-2 dose regimens for treating immune disorders |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| EP3009147A1 (en) | 2014-10-16 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant glioblastoma |
| CA2965170A1 (en) | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| WO2016066671A1 (en) | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| PL3218005T3 (en) | 2014-11-12 | 2023-05-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| GB201420852D0 (en) | 2014-11-24 | 2015-01-07 | Genevillage Kft | Method |
| CN107223123A (en) | 2014-12-09 | 2017-09-29 | 艾伯维公司 | BCL XL inhibitory compounds with low cell permeability and the antibody drug conjugate including it |
| CN113209306A (en) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | Antibody drug conjugates with cell permeable BCL-XL inhibitors |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| WO2016094837A2 (en) | 2014-12-11 | 2016-06-16 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| JP6743015B2 (en) | 2014-12-15 | 2020-08-19 | バイエル ファーマ アクチエンゲゼルシャフト | Antibody drug conjugates (ADCs) with deglycosylated anti-TWEAKR antibody of KSP inhibitor |
| EP3233120A4 (en) | 2014-12-19 | 2018-05-30 | Monash University | Il-21 antibodies |
| EP3237450B1 (en) | 2014-12-22 | 2021-03-03 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| SMT202100094T1 (en) | 2014-12-31 | 2021-03-15 | Checkmate Pharmaceuticals Inc | Combination tumor immunotherapy |
| US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| CA2916283A1 (en) | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
| US10654917B2 (en) | 2015-01-29 | 2020-05-19 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| SG11201704160XA (en) | 2015-03-03 | 2017-06-29 | Kymab Ltd | Antibodies, uses & methods |
| DK3265483T3 (en) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modified von Willebrand factor with improved half-life |
| US10948492B2 (en) | 2015-03-06 | 2021-03-16 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
| GB201503967D0 (en) | 2015-03-09 | 2015-04-22 | Univ Glasgow | Biocompatible implants for use in tendon therapy |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| US11066480B2 (en) | 2015-03-17 | 2021-07-20 | Memorial Sloan Kettering Cancer Center | Anti-MUC16 antibodies and uses thereof |
| US10870706B2 (en) | 2015-03-20 | 2020-12-22 | Pfizer Inc. | Bifunctional cytotoxic agents containing the CTI pharmacophore |
| SI3274370T1 (en) | 2015-03-23 | 2020-02-28 | Bayer Pharma Aktiengesellschaft | Antibodies against CEACAM6 and their use |
| ES2938359T3 (en) | 2015-04-06 | 2023-04-10 | Bioverativ Usa Inc | Humanized anti-C1s antibodies and methods of using them |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| ES2945313T3 (en) | 2015-04-17 | 2023-06-30 | Amgen Res Munich Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| ES2962885T3 (en) | 2015-05-15 | 2024-03-21 | Massachusetts Gen Hospital | Tumor necrosis factor receptor superfamily antagonist antibodies |
| EP3297615A1 (en) | 2015-05-20 | 2018-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for modulation polarization and activation of macrophages |
| WO2016189104A1 (en) | 2015-05-27 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to produce t cells |
| PT3303394T (en) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anti-ctla-4 antibodies and methods of use thereof |
| KR102661078B1 (en) | 2015-05-29 | 2024-05-23 | 애브비 인코포레이티드 | Anti-CD40 antibodies and uses thereof |
| WO2016201282A2 (en) | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| CA2989963A1 (en) | 2015-06-19 | 2016-12-22 | Cytrx Corporation | Delivery systems for controlled drug release |
| CN114917361A (en) | 2015-06-22 | 2022-08-19 | 拜耳医药股份有限公司 | Antibody Drug Conjugates (ADCs) and Antibody Prodrug Conjugates (APDCs) with Enzymatic Cleavable Groups |
| WO2016207094A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
| CN108025086A (en) | 2015-06-23 | 2018-05-11 | 拜耳制药股份公司 | Antibody-active agent conjugates (ADC) of KSP inhibitors and anti-B7H 3 antibodies |
| PE20180452A1 (en) | 2015-06-23 | 2018-03-05 | Bayer Pharma AG | SITE-SPECIFIC HOMOGENEOUS CONJUGATES WITH KSP INHIBITORS |
| GB201511196D0 (en) | 2015-06-25 | 2015-08-12 | Cytosystems Ltd | Monoclonal antibodies |
| JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
| AU2016282869B2 (en) | 2015-06-26 | 2022-08-18 | Sanofi Biotechnology SAS | Monoclonal anti-IL-1RAcP antibodies |
| EP3314250A4 (en) | 2015-06-26 | 2018-12-05 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| FR3038517B1 (en) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
| CN107849104B (en) | 2015-07-06 | 2021-08-27 | Ucb生物制药有限责任公司 | Tau binding antibodies |
| WO2017005732A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| PT3115376T (en) | 2015-07-10 | 2018-11-15 | Merus Nv | Human cd3 binding antibody |
| TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for dll3 and cd3 |
| TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for egfrviii and cd3 |
| TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for cd70 and cd3 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| EP3331536A4 (en) | 2015-08-03 | 2019-03-27 | The Regents of The University of California | COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY |
| WO2018036117A1 (en) | 2016-08-22 | 2018-03-01 | 复旦大学 | Antibody targeted to tissue factor, preparation method therefor, and use thereof |
| KR102434314B1 (en) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | Anti-PD-1 antibodies and methods of using them |
| PT3344654T (en) | 2015-09-02 | 2021-01-26 | Immutep Sas | Anti-lag-3 antibodies |
| BR112018004981A2 (en) | 2015-09-15 | 2018-10-09 | Scholar Rock, Inc. | anti-pro-myostatin / latent myostatin antibodies and uses thereof. |
| CA3214798A1 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
| EP3356412B1 (en) | 2015-09-29 | 2021-07-07 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Targeting metastasis stem cells through a fatty acid receptor (cd36) |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| SG11201803359VA (en) | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
| US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
| EP3165532B1 (en) | 2015-11-03 | 2018-12-19 | Industrial Technology Research Institute | Auristatin derivatives, linker-drugs and ligand-drug conjugates |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2017085566A1 (en) | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520543D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520567D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520546D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520562D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520603D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520542D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520597D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
| GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520536D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520548D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520575D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520545D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520557D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607535D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520570D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| ES2843724T3 (en) | 2015-11-30 | 2021-07-20 | Inst Nat Sante Rech Med | NMDAR antagonists for the treatment of tumor angiogenesis |
| EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| AU2016365318B2 (en) | 2015-12-02 | 2024-04-18 | Board Of Regents, The University Of Texas System | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
| US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
| ES2919323T3 (en) | 2015-12-04 | 2022-07-26 | Seagen Inc | Conjugates of quaternized tubulisin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017096361A1 (en) | 2015-12-04 | 2017-06-08 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| JP6797203B2 (en) | 2015-12-17 | 2020-12-09 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Improvement of systemic sclerosis by death receptor agonist |
| EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
| MX2018008369A (en) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anti-pro/latent myostatin antibodies and methods of use thereof. |
| WO2017121880A1 (en) | 2016-01-15 | 2017-07-20 | Philogen S.P.A | Intestinal antigens for pharmacodelivery applications |
| JP2019507126A (en) | 2016-02-01 | 2019-03-14 | ファイザー・インク | Tubulicin analogues and methods for their preparation |
| CA3011942A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| TWI748984B (en) | 2016-02-03 | 2021-12-11 | 德商安美基研究（慕尼黑）公司 | Bcma and cd3 bispecific t cell engaging antibody constructs |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| US11112409B2 (en) | 2016-02-12 | 2021-09-07 | The Regents Of The University Of California | Systems and compositions for diagnosing pathogenic fungal infection and methods of using the same |
| EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
| KR102424496B1 (en) | 2016-03-02 | 2022-07-25 | 아이덱스 래보러토리즈, 인코포레이티드 | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease |
| US11014088B2 (en) | 2016-03-09 | 2021-05-25 | The Board Of Regents Of The University Of Texas System | Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates |
| US11921116B2 (en) | 2016-03-09 | 2024-03-05 | Memorial Sloan Kettering Cancer Center | Enigma and CDH18 as companion diagnostics for CDK4 inhibitors |
| HUE062976T2 (en) | 2016-03-11 | 2023-12-28 | Scholar Rock Inc | Immunoglobulins bound to TGFbeta1 and their application |
| IL261793B2 (en) | 2016-03-17 | 2025-04-01 | Numab Therapeutics AG | Anti-tnfalpha-antibodies and functional fragments thereof |
| US10787508B2 (en) | 2016-03-17 | 2020-09-29 | Numab Innovation Ag | Anti-TNFα-antibodies and functional fragments thereof |
| CA3011502A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnf.alpha.-antibodies and functional fragments thereof |
| ES2843974T3 (en) | 2016-03-17 | 2021-07-21 | Tillotts Pharma Ag | Anti-TNF alpha antibodies and functional fragments thereof |
| PT3219726T (en) | 2016-03-17 | 2020-12-15 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
| WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
| US10822416B2 (en) | 2016-03-23 | 2020-11-03 | Mabspace Biosciences (Suzhou) Co., Ltd | Anti-PD-L1 antibodies |
| UA125749C2 (en) | 2016-03-24 | 2022-06-01 | Байєр Фарма Акцієнгезелльшафт | Radio-pharmaceutical complexes |
| MX2018011627A (en) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups. |
| MA43835A (en) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES |
| MX394122B (en) | 2016-03-29 | 2025-03-24 | Geltor Inc | PROTEIN EXPRESSION IN GRAM-NEGATIVE BACTERIA IN WHICH THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1 |
| IL262010B (en) | 2016-04-04 | 2022-09-01 | Bioverativ Usa Inc | Anti-complement factor bb antibodies and their uses |
| US20190112572A1 (en) | 2016-04-05 | 2019-04-18 | Pfizer Inc. | Cell culture process |
| US11084879B2 (en) | 2016-04-07 | 2021-08-10 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2017177199A2 (en) | 2016-04-08 | 2017-10-12 | Iti Health, Inc. | Plectin-1 binding antibodies and uses thereof |
| WO2017182834A1 (en) | 2016-04-19 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating resistant glioblastoma |
| JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Giving a bispecific formulation that binds to CD33 and CD3 for use in a modality for the treatment of myeloid leukemia |
| EA037960B1 (en) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Method of treatment of eosinophilic esophagitis using an anti-il-13 antibody |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| SG11201810040WA (en) | 2016-05-11 | 2018-12-28 | Amgen Inc | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
| CN114177308B (en) | 2016-05-17 | 2024-07-09 | 艾伯维生物制药股份有限公司 | Anti-cMet antibody drug conjugates and methods of use thereof |
| JP7032329B2 (en) | 2016-05-25 | 2022-03-08 | インバイオモーション エセ．エレ． | Therapeutic treatment of breast cancer based on the condition of c-MAF |
| TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agent against factor XI/XIa antibody and use thereof |
| WO2017203051A1 (en) | 2016-05-26 | 2017-11-30 | University College Cork - National University Of Ireland, Cork | An engineered gram positive bacterium |
| KR20190014525A (en) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | A bispecific binding protein that binds immuno-regulatory proteins to tumor antigens |
| EP3464362B1 (en) | 2016-05-27 | 2020-12-09 | AbbVie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
| MA45123A (en) | 2016-05-27 | 2019-04-10 | Agenus Inc | ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE |
| NZ748644A (en) | 2016-05-27 | 2023-05-26 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
| AU2017273147B2 (en) | 2016-06-02 | 2024-06-13 | Immunocore Limited | Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein |
| AU2017277916A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
| BR112018075649A2 (en) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anti-b7-h3 antibodies and antibody drug conjugates |
| CN109563167A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti- B7-H3 antibody and antibody drug conjugates |
| CN109562169A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti-CD98 Antibody and Antibody Drug Conjugate |
| WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| CN116284404A (en) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | anti-B7-H3 antibodies and antibody drug conjugates |
| EA201892814A1 (en) | 2016-06-10 | 2019-06-28 | Байер Фарма Акциенгезельшафт | RADIOPHARMACEUTICAL COMPLEXES |
| UA126905C2 (en) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | ANTIBODY TO PD-L1 AND ITS APPLICATION |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US10829563B2 (en) | 2016-06-16 | 2020-11-10 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor |
| SG11201811064TA (en) | 2016-06-20 | 2019-01-30 | F Star Delta Ltd | Binding molecules binding pd-l1 and lag-3 |
| KR102531889B1 (en) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | Anti-PD-L1 and IL-2 cytokines |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN115305229A (en) | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | Antigen-presenting cell-mimicking scaffold and methods of making and using the same |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| WO2018017964A2 (en) | 2016-07-21 | 2018-01-25 | Emory University | Ebola virus antibodies and binding agents derived therefrom |
| GB201613167D0 (en) | 2016-07-29 | 2016-09-14 | Univ Southampton | Cancer and b-cell related disease therapy |
| EP3493853A1 (en) | 2016-08-03 | 2019-06-12 | Pfizer Inc | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
| EA201990470A1 (en) | 2016-08-09 | 2019-09-30 | Сиэтл Дженетикс, Инк. | MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES |
| CN106938051B (en) | 2016-08-22 | 2019-10-11 | 复旦大学 | Antibody-drug conjugates targeting tissue factor |
| US20190225682A1 (en) | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3506920A4 (en) | 2016-09-02 | 2020-05-27 | 180 Therapeutics LP | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3293271A1 (en) | 2016-09-12 | 2018-03-14 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Marker and target as a diagnostic variable and target for therapy of metastatic cancer |
| MY192158A (en) | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| HUE056238T2 (en) | 2016-09-19 | 2022-02-28 | I Mab Biopharma Hangzhou Co Ltd | Anti-gm-csf antibodies and uses thereof |
| EP3515559A4 (en) | 2016-09-20 | 2020-07-15 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS AND METHODS FOR IDENTIFYING, ASSESSING, PREVENTING AND TREATING AML WITH USP10 BIOMARKERS AND MODULATORS |
| EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| ES2982558T3 (en) | 2016-09-21 | 2024-10-16 | Nextcure Inc | Antibodies to Siglec-15 and methods of using them |
| AU2017331739A1 (en) | 2016-09-23 | 2019-03-07 | Csl Limited | Coagulation factor binding proteins and uses thereof |
| KR102551269B1 (en) | 2016-09-29 | 2023-07-05 | 암젠 인크 | Low-viscosity antigen binding proteins and methods for their preparation |
| TWI843168B (en) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
| US20200048332A1 (en) | 2016-10-12 | 2020-02-13 | Bioverativ Usa Inc. | Anti-c1s antibodies and methods of use thereof |
| EP3528850A4 (en) | 2016-10-18 | 2020-06-24 | Seattle Genetics, Inc. | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS |
| JP7374765B2 (en) | 2016-10-26 | 2023-11-07 | リープ セラピューティクス，インコーポレイテッド | Use of beta-catenin as a biomarker to treat cancer using anti-DKK-1 antibodies |
| WO2018078083A1 (en) | 2016-10-28 | 2018-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating multiple myeloma |
| RU2019114863A (en) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | COMBINED TREATMENT WITH ANTIBODY-DRUG CONJUGATES AND PARP INHIBITORS |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| KR102431830B1 (en) | 2016-11-07 | 2022-08-16 | 주식회사 뉴라클사이언스 | Anti-family 19, member A5 antibodies with sequence similarity and methods of use thereof |
| EP3535288A1 (en) | 2016-11-07 | 2019-09-11 | Immunocore Limited | Peptides |
| WO2018087172A1 (en) | 2016-11-09 | 2018-05-17 | Philogen S.P.A | Il2 and tnf mutant immunoconjugates |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| JP7274417B2 (en) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | 4-1BB binding protein and uses thereof |
| EP4289484A3 (en) | 2016-12-07 | 2024-03-06 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| WO2018106864A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| JP7244987B2 (en) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | Multidrug Antibody Drug Conjugates |
| BR112019012328A2 (en) | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anti-ox40 antibodies and their uses |
| PE20191235A1 (en) | 2016-12-21 | 2019-09-11 | Bayer Pharma AG | LIGAND-DRUG CONJUGATES (ADCS) WITH ENZYMATICALLY CLEARABLE GROUPS |
| EP3558387B1 (en) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| WO2018115083A1 (en) | 2016-12-21 | 2018-06-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of gut diseases such as irritable bowel syndrome (ibs) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP2020506716A (en) | 2016-12-22 | 2020-03-05 | ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ | Monoclonal antibodies targeting unique sialoglycosylated cancer-related epitopes on CD43 |
| BR112019012667A2 (en) | 2016-12-23 | 2020-02-11 | Novartis Ag | FACTOR XI ANTIBODIES AND METHODS OF USE |
| JP7069476B2 (en) | 2017-01-06 | 2022-05-18 | 博奥信生物技▲術▼（南京）有限公司 | ErbB2 antibody and its use |
| PT3565592T (en) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Methods for treating metabolic diseases by inhibiting myostatin activation |
| CA3088855A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| CA3049005A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgf.beta.1 inhibitors and use thereof |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| EP3568411B1 (en) | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| CA3049047A1 (en) | 2017-01-20 | 2018-07-26 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-1 antibodies and uses thereof |
| MX2019008773A (en) | 2017-01-24 | 2019-09-18 | Pfizer | Calicheamicin derivatives and antibody drug conjugates thereof. |
| PE20191208A1 (en) | 2017-01-24 | 2019-09-10 | I Mab | ANTI-CD73 ANTIBODIES AND USES OF THEM |
| WO2018141753A1 (en) | 2017-01-31 | 2018-08-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating squamous cell carcinomas |
| JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
| KR20240044544A (en) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | Glycan-interacting compounds and methods of use |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| EP3596121A1 (en) | 2017-03-14 | 2020-01-22 | Bioverativ USA Inc. | Methods for treating complement-mediated diseases and disorders |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| CN110753702B (en) | 2017-03-15 | 2022-09-20 | 清华大学 | anti-TRKB antibodies |
| WO2018167621A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| KR20190133198A (en) | 2017-03-27 | 2019-12-02 | 셀진 코포레이션 | Methods and Compositions for Reducing Immunogenicity |
| EP3604384B1 (en) | 2017-03-30 | 2021-09-08 | NOF Corporation | Hydrophilic polymer derivative having self-immolative acetal linker and composite using same |
| EP3604385B1 (en) | 2017-03-30 | 2024-05-01 | NOF Corporation | Heterobifunctional monodispersed polyethylene glycol and conjugate using the same |
| MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
| EP3607320A4 (en) | 2017-04-03 | 2021-04-21 | The Regents of the University of California | COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer |
| MA50956A (en) | 2017-04-13 | 2020-10-14 | Agenus Inc | ANTI-CD137 ANTIBODIES AND RELATED METHODS OF USE |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
| BR112019022445A2 (en) | 2017-04-27 | 2020-05-12 | Seattle Genetics, Inc. | COMPOSITION OF BINDER-DRUG CONJUGATE, FORMULATION, METHOD TO INHIBIT THE TUMOR CELL OR CANCER CELL MULTIPLICATION OR CAUSE APOPTOSIS IN A TUMOR OR CANCER CELL, AND, PHARMACEUTICAL CONNECTOR COMPOUND |
| EP3615065A1 (en) | 2017-04-28 | 2020-03-04 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| FI3618863T3 (en) | 2017-05-01 | 2023-09-01 | Agenus Inc | Anti-tigit antibodies and methods of use thereof |
| US11918650B2 (en) | 2017-05-05 | 2024-03-05 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
| EP3401328A1 (en) | 2017-05-10 | 2018-11-14 | Bayer Pharma Aktiengesellschaft | One step antibody humanization by golden gate based germline framework region shuffling |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| CA3063849A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| EP3409297A1 (en) | 2017-05-30 | 2018-12-05 | AlfaRim Medial Holding B.V. | The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy |
| WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| KR20250036941A (en) | 2017-05-31 | 2025-03-14 | 주식회사 에스티큐브앤컴퍼니 | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
| JP2020522562A (en) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand |
| EP3634999A1 (en) | 2017-06-07 | 2020-04-15 | Philogen S.p.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| US11325957B2 (en) | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| EP3421607A1 (en) | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
| WO2019005503A1 (en) | 2017-06-29 | 2019-01-03 | Rutgers, The State University Of New Jersey | Compositions and methods targeting g12 signaling for bronchodilator therapy |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Dhodh inhibitor and chk1 inhibitor for treating cancer |
| AU2018306436A1 (en) | 2017-07-27 | 2020-02-13 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
| WO2019023661A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
| CN110945023B (en) | 2017-07-31 | 2023-08-18 | 豪夫迈·罗氏有限公司 | Humanization method based on three-dimensional structure |
| JP2020530028A (en) | 2017-08-09 | 2020-10-15 | メルス ナムローゼ フェンノートシャップ | Antibodies that bind to EGFR and cMET |
| EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| WO2019051041A1 (en) | 2017-09-06 | 2019-03-14 | University Of Cincinnati | Methods of prognosing early stage breast lesions |
| KR20200045520A (en) | 2017-09-07 | 2020-05-04 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | Antibodies to programmed cell death protein 1 |
| PT3681911T (en) | 2017-09-11 | 2024-12-18 | Univ Monash | Binding proteins to the human thrombin receptor, par4 |
| IL297824A (en) | 2017-09-15 | 2023-01-01 | Amgen Inc | Lyophilization process for pharmaceutical formulation of medical protein |
| WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| US20200255785A1 (en) | 2017-09-15 | 2020-08-13 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
| US20200230266A1 (en) | 2017-09-20 | 2020-07-23 | Alfarim Medical Holding B.V. | The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| EP3693013A4 (en) | 2017-10-06 | 2021-06-30 | Ono Pharmaceutical Co., Ltd. | Bispecific antibody |
| CA3078434A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| KR102715492B1 (en) | 2017-10-18 | 2024-10-11 | 씨에스엘 리미티드 | Human serum albumin variants and uses thereof |
| WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
| AU2018361957B2 (en) | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
| IL274376B2 (en) | 2017-11-02 | 2025-03-01 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
| WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
| AU2018372762A1 (en) | 2017-11-22 | 2020-05-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| EP3713603A1 (en) | 2017-11-23 | 2020-09-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | New method for treating dengue virus infection |
| CN111727075B (en) | 2017-11-27 | 2024-04-05 | 普渡制药公司 | Humanized antibodies targeting human tissue factor |
| JP7359449B2 (en) | 2017-11-30 | 2023-10-11 | センチュリオン バイオファーマ コーポレイション | Albumin-binding prodrug of auristatin E derivative |
| CN111712263B (en) | 2017-11-30 | 2024-12-17 | 拉德克斯公司 | Maytansinoids-based drug delivery systems |
| CA3082507A1 (en) | 2017-12-11 | 2019-06-20 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
| EP3502139A1 (en) | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Antibodies to tumour antigens |
| UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
| US12239736B2 (en) | 2018-01-25 | 2025-03-04 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
| JP2021512103A (en) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Antibody drug conjugate (ADCS) containing a NAPPT inhibitor |
| TWI804572B (en) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
| US12246031B2 (en) | 2018-02-13 | 2025-03-11 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| WO2019157772A1 (en) | 2018-02-13 | 2019-08-22 | 和元生物技术（上海）股份有限公司 | Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy |
| US11857565B2 (en) | 2018-02-20 | 2024-01-02 | Seagen Inc. | Hydrophobic Auristatin F compounds and conjugates thereof |
| JP2021514193A (en) | 2018-02-21 | 2021-06-10 | セルジーン コーポレイション | BCMA-binding antibody and its use |
| US20200384030A1 (en) | 2018-02-21 | 2020-12-10 | Cell Design Labs, Inc. | Chimeric transmembrane receptors and uses thereof |
| EP3759125A4 (en) | 2018-02-28 | 2021-12-08 | Dana-Farber Cancer Institute, Inc. | METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS |
| WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
| WO2019170131A1 (en) | 2018-03-07 | 2019-09-12 | 复旦大学 | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof |
| CA3093645A1 (en) | 2018-03-13 | 2019-09-19 | Nof Corporation | Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain |
| CN110272490B (en) | 2018-03-14 | 2021-05-14 | 上海开拓者生物医药有限公司 | Targeted CTLA-4 antibody, preparation method and application thereof |
| KR102742591B1 (en) | 2018-03-16 | 2024-12-17 | 브리스톨-마이어스 스큅 컴퍼니 | Metabolic enzyme activity and disulfide bond reduction during protein production |
| EP3775909B1 (en) | 2018-03-26 | 2023-05-10 | Glycanostics s.r.o. | Means and methods for glycoprofiling of a protein |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| SG11202009625WA (en) | 2018-04-02 | 2020-10-29 | Bristol Myers Squibb Co | Anti-trem-1 antibodies and uses thereof |
| CN110343178B (en) | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | Anti-human LAG-3 monoclonal antibody and application thereof |
| WO2019197965A1 (en) | 2018-04-09 | 2019-10-17 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| US20210228729A1 (en) | 2018-04-12 | 2021-07-29 | Mediapharma S.R.L. | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| US11471506B2 (en) | 2018-04-23 | 2022-10-18 | Emory University | VIP antagonists and uses in treating cancer |
| EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
| AU2019265888A1 (en) | 2018-05-10 | 2020-11-26 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
| TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
| CN110483639A (en) | 2018-05-15 | 2019-11-22 | 复旦大学 | Target antibody and the antibody-drug conjugates and its preparation method and application of AXL |
| SG11202010596PA (en) | 2018-05-16 | 2020-11-27 | Csl Ltd | Soluble complement receptor type 1 variants and uses thereof |
| TWI869346B (en) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| GB201808927D0 (en) | 2018-05-31 | 2018-07-18 | Institute Of Cancer Res Royal Cancer Hospital | Materials and methods for monitoring the development of resistance of cancers to treatment |
| US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| WO2019236417A1 (en) | 2018-06-04 | 2019-12-12 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
| JP7543144B2 (en) | 2018-06-05 | 2024-09-02 | アムジエン・インコーポレーテツド | Regulation of antibody-dependent cellular phagocytosis |
| TWI851577B (en) | 2018-06-07 | 2024-08-11 | 美商思進公司 | Camptothecin conjugates |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| WO2019243159A1 (en) | 2018-06-18 | 2019-12-26 | Bayer Aktiengesellschaft | Binder-drug conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
| TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
| AU2019288677A1 (en) | 2018-06-21 | 2021-01-14 | Yumanity Therapeutics, Inc. | Compositions and methods for the treatment and prevention of neurological disorders |
| WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
| WO2020008083A1 (en) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling |
| EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
| SG11202013231SA (en) | 2018-07-11 | 2021-01-28 | Scholar Rock Inc | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF |
| HRP20212034T1 (en) | 2018-07-11 | 2022-04-01 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
| CA3106048A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| CA3106046A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
| CN110713537B (en) | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | SEMA4D antibody and preparation method and application thereof |
| WO2020016160A1 (en) | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| WO2020016377A1 (en) | 2018-07-19 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
| US12258407B2 (en) | 2018-07-19 | 2025-03-25 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-PD-1 antibodies, dosages and uses thereof |
| BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
| AU2019311077A1 (en) | 2018-07-23 | 2021-02-25 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
| WO2020022499A1 (en) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | Composition for inhibiting aging, preventing, improving, or treating age-related diseases, or extending lifespan |
| MX2021001221A (en) | 2018-07-30 | 2021-06-23 | Amgen Res Munich Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3. |
| JOP20210022A1 (en) | 2018-08-03 | 2021-01-28 | Amgen Inc | Antibody constructs for cldn18.2 and cd3 |
| CA3109999A1 (en) | 2018-08-21 | 2020-02-27 | Abl Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| CA3109732A1 (en) | 2018-08-27 | 2020-03-05 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct |
| CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| WO2020053325A1 (en) | 2018-09-12 | 2020-03-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| EP3854875A4 (en) | 2018-09-21 | 2022-07-06 | National University Corporation Tokyo Medical and Dental University | Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody |
| CA3114295A1 (en) | 2018-09-28 | 2020-04-02 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
| TW202028239A (en) | 2018-09-28 | 2020-08-01 | 美商安進公司 | Antibodies against soluble bcma |
| KR20210070300A (en) | 2018-10-03 | 2021-06-14 | 스태튼 바이오테크놀로지 비.브이. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
| JP7644706B2 (en) | 2018-10-11 | 2025-03-12 | アムジエン・インコーポレーテツド | Downstream processing of bispecific antibody constructs |
| EP3864166A1 (en) | 2018-10-12 | 2021-08-18 | Quidel Corporation | Extraction reagent for use in an assay for detection of group a streptococcus |
| UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
| EP3867277A4 (en) | 2018-10-18 | 2022-09-07 | Sinomab Bioscience Limited | METHOD FOR MODULATING SELF-IMMUNITY BY BREAKAGE OF THE CIS-LIGAND BOND OF SIGLEC-TYPE ANTIGENS |
| MX2021004598A (en) | 2018-10-23 | 2021-06-15 | Scholar Rock Inc | Rgmc-selective inhibitors and use thereof. |
| EP3873944A1 (en) | 2018-10-31 | 2021-09-08 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
| AU2019370859B2 (en) | 2018-10-31 | 2023-09-21 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| US20220000893A1 (en) | 2018-10-31 | 2022-01-06 | |Nserm (Institut National De La Santé Et De La Recherche Médicale) | Method for treating t-helper type 2 mediated disease |
| WO2020095104A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| US20210403546A1 (en) | 2018-11-05 | 2021-12-30 | Ludwig Institute For Cancer Research Ltd. | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
| EP3878869A4 (en) | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | Nkg2a antibody, preparation method therefor and application thereof |
| US20220017629A1 (en) | 2018-11-20 | 2022-01-20 | Shanghai Pharmaexplorer Co., Ltd. | Ox40 antibody, preparation method thereof and use thereof |
| CN111234018A (en) | 2018-11-29 | 2020-06-05 | 上海开拓者生物医药有限公司 | Fully human anti-GITR antibody and preparation method thereof |
| AU2019390274A1 (en) | 2018-11-30 | 2021-07-22 | Abl Bio Inc. | Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof |
| CN111253485A (en) | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | Anti-human TIM-3 monoclonal antibody and application thereof |
| CN113166257B (en) | 2018-12-03 | 2023-05-30 | 上海开拓者生物医药有限公司 | CD47 antibody and preparation method and application thereof |
| WO2020115655A1 (en) | 2018-12-06 | 2020-06-11 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
| US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
| US20220010008A1 (en) | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| CA3124356A1 (en) | 2018-12-20 | 2020-06-25 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
| CN111349162A (en) | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | Humanized anti-PD-1 antibodies and uses thereof |
| CN111434688A (en) | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | CD73 antibody and preparation method and application thereof |
| JP2022522265A (en) | 2019-01-16 | 2022-04-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Erythroferrone mutants and their use |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| CN113348178A (en) | 2019-01-28 | 2021-09-03 | 枫叶生物技术有限公司 | PSMP antagonists for the treatment of fibrotic diseases of the lung, kidney or liver |
| CR20210416A (en) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFß AND USES THEREOF |
| AU2019427766A1 (en) | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| JP7232925B2 (en) | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | Process for preparing antibody drug conjugates with improved homogeneity |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| KR20210143192A (en) | 2019-02-22 | 2021-11-26 | 우한 이지 바이오파마 씨오., 엘티디. | Modified Fc fragments, antibodies comprising same, and applications thereof |
| EP3928790A4 (en) | 2019-02-22 | 2023-01-11 | Wuhan Yzy Biopharma Co., Ltd. | CD3 ANTIGEN-BINDING FRAGMENT AND ITS USE |
| EP4378958A3 (en) | 2019-02-26 | 2024-09-04 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
| WO2020185763A1 (en) | 2019-03-11 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| WO2020193740A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
| EP3947442A2 (en) | 2019-03-28 | 2022-02-09 | Danisco US Inc. | Engineered antibodies |
| AU2020253455A1 (en) | 2019-04-03 | 2021-11-04 | Genzyme Corporation | Anti-alpha beta TCR binding polypeptides with reduced fragmentation |
| GB201904717D0 (en) | 2019-04-03 | 2019-05-15 | Univ London Queen Mary | Treatment and diagnosis of mental disorders |
| TWI862565B (en) | 2019-04-04 | 2024-11-21 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
| WO2020208082A1 (en) | 2019-04-09 | 2020-10-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating cmv related diseases |
| CA3136691A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
| TW202110873A (en) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | Chimeric receptors and methods of use thereof |
| WO2020223121A1 (en) | 2019-04-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| MX2021013657A (en) | 2019-05-10 | 2022-02-21 | Takeda Pharmaceuticals Co | Antibody drug conjugates. |
| WO2020229648A1 (en) | 2019-05-16 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat type 2 inflammation or mast-cell dependent disease |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| CU20210096A7 (en) | 2019-05-21 | 2022-06-06 | Novartis Ag | CD19 BINDING MOLECULES |
| EP3976181A1 (en) | 2019-05-24 | 2022-04-06 | Sanofi | Methods for treating systemic sclerosis |
| WO2020243594A1 (en) | 2019-05-30 | 2020-12-03 | Viti Incorporated | Methods for detecting a mycobacterium tuberculosis infection |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| AU2020290573A1 (en) | 2019-06-13 | 2021-11-04 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
| WO2020254861A1 (en) | 2019-06-19 | 2020-12-24 | Ovatrition Ltd. | Antibody-mediated neutralization of beta-lactamases |
| GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| BR112021024997A2 (en) | 2019-07-03 | 2022-01-25 | Oxford Biotherapeutics Ltd | Antibodies, polynucleotide, expression vector, host cell, pharmaceutical composition, methods and use |
| WO2021001539A1 (en) | 2019-07-04 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy to detect and treat eosinophilic fasciitis |
| TWI845231B (en) | 2019-07-05 | 2024-06-11 | 日商小野藥品工業股份有限公司 | Treatment of hematological cancer with pd-1/cd3 bispecific protein |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP2022546002A (en) | 2019-07-11 | 2022-11-02 | 武▲漢▼友芝友生物制▲薬▼有限公司 | tetravalent symmetric bispecific antibody |
| MX2022000779A (en) | 2019-07-19 | 2022-02-14 | Sinocelltech Ltd | Humanized anti-vegf monoclonal antibody. |
| CN114127106B (en) | 2019-07-19 | 2024-01-12 | 神州细胞工程有限公司 | Humanized anti-VEGF Fab antibody fragments and uses thereof |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2021018035A1 (en) | 2019-07-26 | 2021-02-04 | 神州细胞工程有限公司 | Humanized anti-il17a antibody and use thereof |
| EP4004041A1 (en) | 2019-07-26 | 2022-06-01 | Amgen Inc. | Anti-il13 antigen binding proteins |
| CN114341186A (en) | 2019-07-30 | 2022-04-12 | 魁尔斯弗生物治疗股份有限公司 | Bispecific anti-LRRC 15 and CD3 epsilon antibodies |
| US20220281977A1 (en) | 2019-07-30 | 2022-09-08 | Ono Pharmaceutical Co., Ltd. | Bispecific antibody |
| GB201910899D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| WO2021023860A1 (en) | 2019-08-07 | 2021-02-11 | Db Biotech, As | Improved horseradish peroxidase polypeptides |
| WO2021025140A1 (en) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | Dual-specific protein |
| CR20220076A (en) | 2019-08-30 | 2022-06-24 | Agenus Inc | ANTI-CD96 ANTIBODIES AND THEIR METHODS OF USE |
| GB201912657D0 (en) | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
| CN117683133A (en) | 2019-09-03 | 2024-03-12 | 百奥泰生物制药股份有限公司 | anti-TIGIT immunosuppressant and application |
| US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
| WO2021044012A1 (en) | 2019-09-05 | 2021-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment and pronostic of acute myeloid leukemia |
| GB201912882D0 (en) | 2019-09-06 | 2019-10-23 | Scancell Ltd | Ssea-4 binding members |
| US20220306741A1 (en) | 2019-09-10 | 2022-09-29 | Amgen Inc. | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity |
| EP3792632A1 (en) | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
| TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
| EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| AU2020348457A1 (en) | 2019-09-19 | 2022-04-07 | Leap Therapeutics, Inc. | Use of DKK-1 inhibitors for treating cancer |
| KR20220084056A (en) | 2019-09-19 | 2022-06-21 | 씨젠 인크. | Selective drug release from internalized biologically active compound conjugates |
| US20220362397A1 (en) | 2019-09-26 | 2022-11-17 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol having peptide linker |
| EP4041767A1 (en) | 2019-09-26 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| CA3152316A1 (en) | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
| WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| KR20220088438A (en) | 2019-10-09 | 2022-06-27 | 주식회사 에스티큐브앤컴퍼니 | Antibodies specific for glycosylated LAG3 and methods of use thereof |
| GB201915163D0 (en) | 2019-10-18 | 2019-12-04 | Univ Southampton | Cancer vaccine |
| WO2021097344A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
| PE20221462A1 (en) | 2019-11-15 | 2022-09-21 | Pliant Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE ACTIVATION OF INTEGRINS |
| JP2023502666A (en) | 2019-11-22 | 2023-01-25 | リープ セラピューティクス，インコーポレイテッド | Methods of treating cancer with DKK-1 inhibitors |
| US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
| CN115298213A (en) | 2019-12-19 | 2022-11-04 | 奎多公司 | Monoclonal antibody fusion |
| AR120832A1 (en) | 2019-12-20 | 2022-03-23 | Amgen Inc | MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS |
| JP2023508366A (en) | 2019-12-27 | 2023-03-02 | アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク | Methods for producing bispecific FCYRIIIxCD30 antibody constructs |
| CN113045655A (en) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
| BR112022012885A2 (en) | 2019-12-30 | 2022-09-06 | Seagen Inc | METHOD FOR TREATMENT OF A CANCER THAT EXPRESSES CD70 IN A SUBJECT, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A CANCER THAT EXPRESSES CD70, E, KIT |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| US20230057012A1 (en) | 2020-01-11 | 2023-02-23 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
| AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
| TWI793503B (en) | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | ANTI-IL-1β ANTIBODIES |
| EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| WO2021150925A1 (en) | 2020-01-24 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Uses of biomarkers for improving immunotherapy |
| US20230086099A1 (en) | 2020-01-30 | 2023-03-23 | Ona Therapeutics, S.L. | Combination therapy for treatment of cancer and cancer metastasis |
| BR102020002165A2 (en) | 2020-01-31 | 2021-11-30 | Fundação Oswaldo Cruz | ANTIBODY, ITS USE, PHARMACEUTICAL COMPOSITION INCLUDING IT, METHOD OF DIAGNOSING FUNGAL INFECTIONS, DIAGNOSIS KIT OF FUNGAL INFECTIONS AND METHOD FOR TREATMENT OF FUNGAL INFECTIONS. |
| CA3168882A1 (en) | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
| WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| EP4114445A1 (en) | 2020-03-06 | 2023-01-11 | Ona Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
| CA3173981A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
| JP2023517611A (en) | 2020-03-10 | 2023-04-26 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | IL-6/IL-6R antibody compositions and methods of use |
| EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| CA3175275A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
| US20230192833A1 (en) | 2020-03-20 | 2023-06-22 | Centre National De La Recherche (Cnrs) | New anti-VEGFC antibodies and uses thereof |
| US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
| US20240261424A1 (en) | 2020-03-30 | 2024-08-08 | National Cancer Center | Antibody drug conjugate |
| CN115362171A (en) | 2020-03-31 | 2022-11-18 | 百奥泰生物制药股份有限公司 | Antibody for treating coronavirus, fusion protein and application thereof |
| WO2021207701A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
| AU2021257848A1 (en) | 2020-04-15 | 2022-12-01 | Voyager Therapeutics, Inc. | Tau binding compounds |
| JP2023522029A (en) | 2020-04-17 | 2023-05-26 | ゾエティス・サービシーズ・エルエルシー | canine antibody variant |
| CA3176434A1 (en) | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Feline antibody variants |
| GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
| WO2021218883A1 (en) | 2020-04-28 | 2021-11-04 | 神州细胞工程有限公司 | TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN |
| US20210340586A1 (en)* | 2020-04-30 | 2021-11-04 | Sutro Biopharma, Inc. | Methods of Producing Full-Length Antibodies Using E. coli |
| EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| WO2021234178A1 (en) | 2020-05-22 | 2021-11-25 | Philogen S.P.A | TNFα IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS |
| AU2021281554A1 (en) | 2020-05-29 | 2022-12-15 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3 |
| CN113754766A (en) | 2020-06-02 | 2021-12-07 | 明慧医药（上海）有限公司 | Anti-B7-H3 antibody and its preparation and application |
| EP3919062A1 (en) | 2020-06-02 | 2021-12-08 | Institut Gustave-Roussy | Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom |
| US20230302031A1 (en) | 2020-06-02 | 2023-09-28 | Institut Gustave-Roussy | Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome |
| US20230190804A1 (en) | 2020-06-17 | 2023-06-22 | Tiziana Life Sciences Plc | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies |
| WO2021255204A1 (en) | 2020-06-18 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
| EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
| EP3933035A1 (en) | 2020-07-03 | 2022-01-05 | Aarhus Universitet | Compositions comprising extracellular vesicles and sting stimulatory agents |
| JP2023535792A (en) | 2020-07-30 | 2023-08-21 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | Anti-CD3 antibody for coronavirus therapy |
| CN116724236A (en) | 2020-08-06 | 2023-09-08 | 美国比奥维拉迪维股份有限公司 | Inflammatory cytokines and fatigue in subjects with complement-mediated diseases |
| CN114057877A (en) | 2020-08-07 | 2022-02-18 | 百奥泰生物制药股份有限公司 | anti-PD-L1 antibody and application thereof |
| US12221463B2 (en) | 2020-08-07 | 2025-02-11 | The Board Of Regents Of The University Of Oklahoma | Method of promoting wound healing by inhibiting CCR3 |
| KR20230069171A (en) | 2020-09-15 | 2023-05-18 | 바이엘 악티엔게젤샤프트 | Novel anti-A2AP antibodies and uses thereof |
| KR20230079148A (en) | 2020-09-28 | 2023-06-05 | 조에티스 서비시즈 엘엘씨 | canine antibody variants |
| AR123645A1 (en) | 2020-09-29 | 2022-12-28 | Zoetis Services Llc | FELINE ANTIBODIES VARIANTS |
| CN116368154A (en) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | trispecific binder |
| US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| WO2022081436A1 (en) | 2020-10-15 | 2022-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
| WO2022082005A1 (en) | 2020-10-16 | 2022-04-21 | Qlsf Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
| WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
| US20230406929A1 (en) | 2020-11-06 | 2023-12-21 | Amgen Inc. | Polypeptide constructs binding to cd3 |
| CR20230229A (en) | 2020-11-06 | 2023-09-05 | Amgen Res Munich Gmbh | BISPECIFIC ANTIGEN-BINDING MOLECULES WITH MULTIPLE TARGETS OF INCREASED SELECTIVITY |
| WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
| IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2023551113A (en) | 2020-11-06 | 2023-12-07 | バイオ－テラ ソリュ－ションズ，エルティーディー． | Bispecific antibodies and their applications |
| CR20230235A (en) | 2020-11-06 | 2023-10-05 | Amgen Res Munich Gmbh | POLYPEPTIDE CONSTRUCTIONS THAT SELECTIVELY BIND CLDN6 AND CD3 |
| JP7397996B2 (en) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | antibody drug conjugate |
| CA3202089A1 (en) | 2020-11-20 | 2022-05-27 | Zoetis Services Llc | Bovine antibody variants |
| GB202018395D0 (en) | 2020-11-23 | 2021-01-06 | Scancell Ltd | Immunotherapy |
| JPWO2022124247A1 (en) | 2020-12-09 | 2022-06-16 | | |
| MX2023007181A (en) | 2020-12-16 | 2023-08-30 | Voyager Therapeutics Inc | Tau binding compounds. |
| JP2024503212A (en) | 2020-12-18 | 2024-01-25 | ゾエティス・サービシーズ・エルエルシー | Mutations in the constant region of feline antibodies |
| AU2021401316A1 (en) | 2020-12-18 | 2023-07-06 | Kiniksa Pharmaceuticals, Gmbh | Protein compositions and methods for producing and using the same |
| US20240092892A1 (en) | 2020-12-30 | 2024-03-21 | Bio-Thera Solutions, Ltd. | Anti-cldn18.2 antibody, and preparation method therefor and use thereof |
| AU2022208361A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Anti-dll3 antibody-drug conjugate |
| CN114763381B (en) | 2021-01-13 | 2025-01-28 | 博生吉医药科技(苏州)有限公司 | B7-H3 chimeric antigen receptor modified T cells and their applications |
| KR20230146521A (en) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | Antibody-pyrrolobenzodiazepine derivative conjugate |
| JP2024503508A (en) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | Immunomodulatory antibody-drug conjugates |
| UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
| US20240082347A1 (en) | 2021-01-22 | 2024-03-14 | Royal College Of Surgeons In Ireland | Treatment of coronavirus |
| KR20230136604A (en) | 2021-01-28 | 2023-09-26 | 조에티스 서비시즈 엘엘씨 | Mutations in the canine antibody constant region |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| JP2024506300A (en) | 2021-02-03 | 2024-02-13 | シージェン インコーポレイテッド | Immune stimulating compounds and conjugates |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2022180172A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| KR20230165212A (en) | 2021-03-02 | 2023-12-05 | 다나-파버 캔서 인스티튜트 인크. | How to treat red blood cell disorders |
| JP2024512324A (en) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
| BR112023017490A2 (en) | 2021-03-17 | 2023-11-07 | Receptos Llc | METHODS OF TREATMENT OF ATOPIC DERMATITIS WITH ANTI IL-13 ANTIBODIES |
| BR112023018842A2 (en) | 2021-03-18 | 2023-12-26 | Seagen Inc | SELECTIVE DRUG RELEASE OF CONJUGATES |
| JP2024510435A (en) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | Selective drug release from internalization complexes of bioactive compounds |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| MX2023011619A (en) | 2021-03-30 | 2023-10-11 | Bayer Ag | Anti-sema3a antibodies and uses thereof. |
| JP2024513837A (en) | 2021-03-31 | 2024-03-27 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | Reducing surgery-related hemolysis in patients with cold agglutinin disease |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4314078A1 (en) | 2021-04-02 | 2024-02-07 | Amgen Inc. | Mageb2 binding constructs |
| AU2022258552A1 (en) | 2021-04-12 | 2023-10-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
| WO2022221409A1 (en) | 2021-04-14 | 2022-10-20 | Villaris Therapeutics, Inc. | Anti-cd122 antibodies and uses thereof |
| WO2022219076A1 (en) | 2021-04-14 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
| US20240228659A1 (en) | 2021-04-14 | 2024-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve nk cells cytotoxicity |
| US20220332822A1 (en) | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| JP2024514673A (en) | 2021-04-20 | 2024-04-02 | シージェン インコーポレイテッド | Regulation of antibody-dependent cellular cytotoxicity |
| AU2022270075A1 (en) | 2021-05-04 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| AU2022269312A1 (en) | 2021-05-06 | 2023-10-19 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
| JP2024520562A (en) | 2021-05-28 | 2024-05-24 | シージェン インコーポレイテッド | Anthracycline Antibody Conjugates |
| WO2022253910A1 (en) | 2021-06-02 | 2022-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A new method to treat an inflammatory skin disease |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| US20240280561A1 (en) | 2021-06-08 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| AU2022293999A1 (en) | 2021-06-14 | 2023-11-30 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
| US12043671B2 (en) | 2021-06-16 | 2024-07-23 | Gundersen Lutheran Medical Foundation, Inc. | Antibodies targeting an amphiregulin-derived cell surface neo-epitope |
| IL309078A (en) | 2021-06-23 | 2024-02-01 | Scholar Rock Inc | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| AU2022304582A1 (en) | 2021-06-29 | 2024-02-01 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| WO2023285620A2 (en) | 2021-07-14 | 2023-01-19 | Alchemab Therapeutics Ltd. | Compositions and methods for targeting viral proteins |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
| EP4377338A2 (en) | 2021-07-27 | 2024-06-05 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
| AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| CN115702931A (en) | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | Application of anti-PD-L1/CD47 bispecific antibody in the treatment of diseases |
| JP2024529771A (en) | 2021-08-26 | 2024-08-08 | グリカノスティクス エス．アール．オー． | Glycoprotein biomarkers for cancer diagnosis |
| CA3230117A1 (en) | 2021-09-02 | 2023-03-09 | Mark Trautwein | Anti-cecam6 antibodies with reduced side-effects |
| KR20240109604A (en) | 2021-09-03 | 2024-07-11 | 고 테라퓨틱스, 인크. | Anti-glyco-cMET antibodies and uses thereof |
| KR20240101546A (en) | 2021-09-03 | 2024-07-02 | 고 테라퓨틱스, 인크. | Anti-glyco-LAMP1 antibodies and uses thereof |
| EP4398889A1 (en) | 2021-09-10 | 2024-07-17 | Leap Therapeutics, Inc. | Combination therapy |
| US20240385193A1 (en) | 2021-09-14 | 2024-11-21 | Glycanostics S.R.O. | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| EP4405391A1 (en) | 2021-09-20 | 2024-07-31 | Eli Lilly and Company | Anti-il-1-beta antibodies |
| JP2024534661A (en) | 2021-09-30 | 2024-09-20 | バイオ－テラ ソリュ－ションズ，エルティーディー． | Anti-B7-H3 antibody and its applications |
| US20240401146A1 (en) | 2021-10-06 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| WO2023064942A1 (en) | 2021-10-14 | 2023-04-20 | Tiziana Life Sciences Plc | Methods of suppressing microglial activation |
| IL312515A (en) | 2021-11-03 | 2024-07-01 | Affimed Gmbh | Bispecific CD16A binders |
| WO2023078906A1 (en) | 2021-11-03 | 2023-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating acute myeloid leukemia |
| AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| WO2023079058A1 (en) | 2021-11-05 | 2023-05-11 | Yokogawa Insilico Biotechnology Gmbh | Cell culture with reduced production of lactate |
| MX2024005635A (en) | 2021-11-09 | 2024-07-29 | Sensei Biotherapeutics Inc | ANTI-VISA ANTIBODIES AND THEIR USES. |
| WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
| WO2023089159A1 (en) | 2021-11-22 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy targeting stroma/tumor cell crosstalk to treat a cancer |
| EP4440594A2 (en) | 2021-11-29 | 2024-10-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| CN116333135A (en) | 2021-12-24 | 2023-06-27 | 百奥泰生物制药股份有限公司 | anti-FR alpha antibody, antibody drug conjugate and application thereof |
| CN118984837A (en) | 2022-01-28 | 2024-11-19 | 乔治穆内公司 | Antibodies to programmed cell death protein 1 as PD-1 agonists |
| WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
| KR20250005991A (en) | 2022-03-09 | 2025-01-10 | 가부시키가이샤 큐어드 | Humanized antibodies or functional fragments thereof, antibody-drug complexes and chimeric antigen receptors that bind to Eva1 protein |
| EP4476260A1 (en) | 2022-03-11 | 2024-12-18 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| CN119278055A (en) | 2022-03-17 | 2025-01-07 | 思进公司 | Camptothecin conjugate |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| EP4522651A1 (en) | 2022-05-12 | 2025-03-19 | Amgen Research (Munich) GmbH | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
| EP4534105A1 (en) | 2022-06-01 | 2025-04-09 | Bio-Thera Solutions, Ltd. | Anti-cldn18.2 antibody, and antibody-drug conjugate and use thereof |
| JPWO2023234426A1 (en) | 2022-06-03 | 2023-12-07 | | |
| EP4537842A1 (en) | 2022-06-07 | 2025-04-16 | Institute of Science Tokyo | Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging |
| AU2023293090A1 (en) | 2022-06-15 | 2025-01-30 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| IL317947A (en) | 2022-06-24 | 2025-02-01 | Bioverativ Usa Inc | Methods for treating complement-mediated diseases |
| KR20250039992A (en) | 2022-06-29 | 2025-03-21 | 액토움 게엠베하 | Detection of biomolecules in single cells |
| WO2024003380A1 (en) | 2022-06-30 | 2024-01-04 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection |
| CN119768423A (en) | 2022-07-12 | 2025-04-04 | 飞跃治疗公司 | Combination therapy |
| EP4538291A1 (en) | 2022-07-14 | 2025-04-16 | Bio-Thera Solutions, Ltd. | Anti-nectin-4 antibody, and antibody-drug conjugate and use thereof |
| WO2024012539A1 (en) | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | Anti-nectin-4 antibody and use thereof |
| CN117982672A (en) | 2022-07-14 | 2024-05-07 | 百奥泰生物制药股份有限公司 | Anti-Nectin-4 antibody-drug conjugates and their applications |
| WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
| WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
| TW202412762A (en) | 2022-07-27 | 2024-04-01 | 香港商祐方有限公司 | Auristatin derivatives and conjugates thereof |
| WO2024030982A2 (en) | 2022-08-02 | 2024-02-08 | Diadem Spa | Device for detection and prognostic assessment of neurodegenerative disorders |
| AU2023320054A1 (en) | 2022-08-03 | 2025-02-06 | Regents Of The University Of Minnesota | Immunostimulatory anti-pd-l1-drug conjugates |
| WO2024028476A1 (en) | 2022-08-05 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of th2-mediated diseases |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| WO2024037910A1 (en) | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
| TW202417488A (en) | 2022-08-23 | 2024-05-01 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
| WO2024044687A1 (en) | 2022-08-26 | 2024-02-29 | Valo Health, Inc. | Biomarker combinations for prognosis and management of diabetic retinopathy |
| AU2023334858A1 (en) | 2022-09-01 | 2025-03-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| CN116836286A (en) | 2022-09-07 | 2023-10-03 | 中国科学院合肥物质科学研究院 | Antibodies capable of specifically binding to ROR1, drug conjugates thereof, preparation methods and applications thereof |
| WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
| IL319121A (en) | 2022-09-15 | 2025-04-01 | Voyager Therapeutics Inc | Tau binding compounds |
| AR130550A1 (en) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USE |
| TW202432099A (en) | 2022-10-25 | 2024-08-16 | 美商默沙東有限責任公司 | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024105205A1 (en) | 2022-11-17 | 2024-05-23 | Bayer Aktiengesellschaft | Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| US20240207425A1 (en) | 2022-12-14 | 2024-06-27 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
| TW202430247A (en) | 2022-12-22 | 2024-08-01 | 美商供石公司 | Selective and potent inhibitors of myostatin activation |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| WO2024133858A1 (en) | 2022-12-22 | 2024-06-27 | Julius-Maximilians-Universität-Würzburg | Antibodies for use as coagulants |
| US20240247069A1 (en) | 2023-01-13 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2024161015A1 (en) | 2023-02-03 | 2024-08-08 | Institut National de la Santé et de la Recherche Médicale | Method to treat age-related diseases |
| WO2024167898A1 (en) | 2023-02-07 | 2024-08-15 | Go Therapeutics, Inc. | ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES |
| TW202440633A (en) | 2023-03-08 | 2024-10-16 | 美商安進公司 | Controlled-ice nucleation lyophilization process for bispecific molecules |
| WO2024184479A1 (en) | 2023-03-08 | 2024-09-12 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of food allergy |
| GB202303784D0 (en) | 2023-03-15 | 2023-04-26 | Institute Of Cancer Res Royal Cancer Hospital | Cancer treatment |
| EP4431526A1 (en) | 2023-03-16 | 2024-09-18 | Emfret Analytics GmbH & Co. KG | Anti-gpvi antibodies and functional fragments thereof |
| WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024206126A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Cd16-binding antibodies and uses thereof |
| WO2024218706A1 (en) | 2023-04-21 | 2024-10-24 | Pfizer Inc. | Improved cells and cell cultures |
| WO2024236131A1 (en) | 2023-05-17 | 2024-11-21 | Institut National de la Santé et de la Recherche Médicale | Stratificate and method to treat a patient suffering from a cancer |
| WO2024246162A1 (en) | 2023-05-30 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of focal cortical dysplasia |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2024256527A1 (en) | 2023-06-13 | 2024-12-19 | Institut National de la Santé et de la Recherche Médicale | Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy |
| WO2024259378A1 (en) | 2023-06-14 | 2024-12-19 | Amgen Inc. | T cell engager masking molecules |
| WO2025021839A1 (en) | 2023-07-25 | 2025-01-30 | Institut National de la Santé et de la Recherche Médicale | Method to treat metabolic disorders |
| WO2025034542A1 (en) | 2023-08-04 | 2025-02-13 | Cornell University | Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy |
| WO2025032112A1 (en) | 2023-08-08 | 2025-02-13 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of type 2-mediated diseases |
| WO2025040820A1 (en) | 2023-08-23 | 2025-02-27 | Granular Therapeutics Limited | Anti-cd203c antibody conjugates and uses thereof |
| WO2025054181A1 (en) | 2023-09-05 | 2025-03-13 | Seagen Inc. | Targeted degrader molecules and ligand drug conjugates thereof |
| WO2025068418A1 (en) | 2023-09-27 | 2025-04-03 | Institut National de la Santé et de la Recherche Médicale | Inhibitor of the transcription factor ap-1 for use in the treatment of age-related diseases |